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ABSTRACT
CANCER RISK PREDICTION WITH WHOLE EXOME SEQUENCING AND
MACHINE LEARNING
by
Abdulrhman Fahad M Aljouie
Accurate cancer risk and survival time prediction are important problems in personalized
medicine, where disease diagnosis and prognosis are tuned to individuals based on their
genetic material. Cancer risk prediction provides an informed decision about making
regular screening that helps to detect disease at the early stage and therefore increases the
probability of successful treatments. Cancer risk prediction is a challenging problem.
Lifestyle, environment, family history, and genetic predisposition are some factors that
influence the disease onset. Cancer risk prediction based on predisposing genetic variants
has been studied extensively. Most studies have examined the predictive ability of variants
in known mutated genes for specific cancers. However, previous studies have not explored
the predictive ability of collective genomic variants from whole-exome sequencing data. It
is crucial to train a model in one study and predict another related independent study to
ensure that the predictive model generalizes to other datasets. Survival time prediction
allows patients and physicians to evaluate the treatment feasibility and helps chart health
treatment plans. Many studies have concluded that clinicians are inaccurate and often
optimistic in predicting patients’ survival time; therefore, the need increases for automated
survival time prediction from genomic and medical imaging data.
For cancer risk prediction, this dissertation explores the effectiveness of ranking
genomic variants in whole-exome sequencing data with univariate features selection

methods on the predictive capability of machine learning classifiers. The dissertation
performs cross-study in chronic lymphocytic leukemia, glioma, and kidney cancers that
show that the top-ranked variants achieve better accuracy than the whole genomic variants.
For survival time prediction, many studies have devised 3D convolutional neural
networks (CNNs) to improve the accuracy of structural magnetic resonance imaging (MRI)
volumes to classify glioma patients into survival categories. This dissertation proposes a
new multi-path convolutional neural network with SNP and demographic features to
predict glioblastoma survival groups with a one-year threshold that improves upon existing
machine learning methods. The dissertation also proposes a multi-path neural network
system to predict glioblastoma survival categories with a 14-year threshold from a
heterogeneous combination of genomic variations, messenger ribonucleic acid (RNA)
expressions, 3D post-contrast T1 MRI volumes, and 2D post-contrast T1 MRI modality
scans that show the malignancy. In 10-fold cross-validation, the mean 10-fold accuracy of
the proposed network with handpicked 2D MRI slices (that manifest the tumor), mRNA
expressions, and SNPs slightly improves upon each data source individually.
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CHAPTER 1
INTRODUCTION

Deep learning convolutional neural network (CNN) and existing machine learning
methods such as support vector machine (SVM) and random forest (RF) successfully
applied to a wide range of fields [1-4]. With the high availability of genomic and medical
imaging data, the need increases for automated and accurate cancer risk and survival time
predictions.

1.1 Cancer Risk Prediction
Cancer is the second leading cause of death in the United States [5]. The dissertation
explores chronic lymphocytic leukemia, kidney cancer, and brain cancer risk predictions.
Chronic lymphocytic leukemia accounts for 1.2% of all projected new cancer cases and
0.7% of projected cancer deaths in 2018 in the United States [5]. Kidney and renal pelvis
account for 3.7% of the expected new cancer cases and 2.4% of estimated cancer deaths
in the United States in 2018 [5]. Brain and other nervous system cancer new expected
cases is 1.3% of all cancer new incidents, and 2.7% of all cancer deaths in 2018 [5].
Recent advances in deoxyribonucleic acid (DNA) sequencing technologies
allowed sequencing massive parallel DNA fragments, which reduced the time and cost to
generate human whole-genome and whole-exome sequencing data. A DNA sequence
consists of a chain of letters from four nucleotides: adenine (A), guanine (G), cytosine
(C), and thymine (T). The human genome comprises about three billion base pairs, and
only identical twins may have the same or very similar DNA sequence. There are

1

different types of variation between human genomes. The most common variation type is
Single Nucleotide Polymorphism (SNPs), which is a substitution at a specific locus of the
genome. When comparing two human genomes, an SNP happens once about every 1000
nucleotides. The other types of variations, which involve one or more base pairs, are
insertion, deletion, duplication, translocation, inversion, and copy number. Causes of
many genetic differences in humans are vital in explaining heritable disease susceptibility
and the presence of specific phenotypic traits. Linkage analysis and genome-wide
association studies (GWAS) revealed more than 450 mutations [6], which predispose to
glioma [7], colorectal [8], beast [9], ovarian [7], and other cancers types [6].
Areas of increasing interest in personalized medicine that utilizes DNA
sequencing data are cancer risk prediction, gene editing, and cancer targeted therapy.
Cancer risk prediction is vital to recommend specific regular checkups and tests for
individuals with a high risk for a particular disease that could lead to early detection,
which could enhance treatment outcomes.
The dissertation proposes the use of univariate ranking of genomic variations by
computing Pearson correlation absolute value and chi-squared test statistic between each
variant site and cancer status to weed out noisy features and reduce variants set
dimensionality. The analysis shows that by decreasing variants' data set dimensionality
support vector machine, and random forest classifiers achieved better classification
performance.

2

1.2 Cancer Survival Time Estimation
Predicting glioma survival time helps patients and their clinicians evaluate available
treatment plans and make informed choices. Glioblastoma multiforme (GBM) is the most
common and aggressive type of brain cancer, with a median survival rate of 15 months
[10]. Most advanced cancer patients prefer to know their estimated survival time [11].
However, clinicians’ survival time estimates are inaccurate, and often optimistic [11, 12].
Many studies have devised 3D convolutional neural networks (CNNs) to improve the
accuracy of structural magnetic resonance imaging (MRI) volumes to classify glioma
patients into survival categories [3, 13-15].
This dissertation proposes a multi-path neural network system to predict
glioblastoma survival categories from a heterogeneous combination of genomic
variations, messenger ribonucleic acid (RNA) expressions, 3D post-contrast T1 MRI
volumes, and 2D post-contrast T1 MRI modality scans that show the malignancy. The
dissertation also proposes a new multi-path convolutional neural network with
demographic features and SNP data to predict glioblastoma survival groups that
improved upon SVM and random forest prediction accuracy.

1.3 Dissertation Contribution and Outline
The contribution of this dissertation is four-fold: 1) to investigate the predictive ability of
support vector machine model and the effect of ranking SNPs with Pearson’s correlation
coefficient and chi-squared statistics in normal versus tumor samples in chronic
lymphocytic leukemia (CLL) and kidney cancer subtypes, 2) to compare support vector
machine and random forests prediction accuracy of germline SNPs in glioma subtypes

3

cases and healthy controls from the 1000 Genomes Project [16], 3) to propose a multipath neural network from heterogeneous data sources: SNP, gene expression, 2D
magnetic resonance imaging (MRI) scans, and 3D MRI volumes to classify glioma
patients into short- versus long-term survival groups, and 4) to propose a new multi-path
convolutional neural network for glioblastoma survival group prediction with SNP and
demographic features.
In Chapter 2, the dissertation provides a problem description and a literature
review. In Chapter 3, the dissertation proposes using SVM and feature selection to
predict normal and tumor samples obtained from exome sequences variants in chronic
lymphocytic leukemia (CLL). In Chapter 4, the study investigates the effectiveness of
ranking SNPs on the predictive ability of SVM in kidney cancer subtypes normal and
tumor samples. Chapter 5 compares the prediction accuracy of random forests and SVM
in top-ranked SNPs to classify glioma subtypes individuals (cases) and healthy
individuals (controls) from the 1000 Genomes Project. Chapter 6 proposes a multi-path
neural network of combined neuroimaging, SNP, gene expression data to predict
glioblastomas survival groups at the 14-year threshold. In Chapter 7, the dissertation
devises a multi-path neural network architecture to predict short- and long-term survival
classes in glioblastomas with multi-modal data.

4

CHAPTER 2
BACKGROUND

Human genomes differ among individuals in the population. The variations in human
genomes give a rise to many phenotypic traits and diseases. First-degree relatives have
the most similar genomes when compared to the population. Different types of variations
occur between individuals’ DNA sequences, such as substitution, insertion, deletion,
translocation, inversion, and duplication. Figure 2.1 shows a toy example of human DNA
variations.

Figure 2.1 Example of different human DNA variations, bases on red color represent the
change occurred to the original sequence (in green shade background). Underlined bases
represent the repeated subsequence in the DNA sequence. Bases with strikethrough
represent deleted nucleotides from the original sequence.
Substitution, also called single nucleotide polymorphism (SNP), involves a one
base change in the DNA sequence that can be a transition or transversion. Transition is a
type of a SNP where the base change is between purines bases [A, G] or pyrimidines [C,
5

T] bases. Transversion is single change in the DNA sequence that is between purine and
pyrimidines bases. Even though the number of possible transversion are higher,
transitions happen more frequently in human genome [17].
A single change in the DNA sequence results in missense, nonsense, or silent
mutation. Missense and nonsense mutations alter the protein sequence and are more
likely to effect protein function. Silent mutations do not modify amino acid sequence and
often have no effect on protein function; however, these mutations can make a
phenotypic change such as increasing/decreasing protein synthesis time [18].
Insertion/deletion (InDel) variations, which are the second common variations in
human genome [19], are insertion, adding a subsequence to the DNA, or deletion,
removing a subsequence from the DNA.
Translocations happen when a part of the DNA sequence is moved from one
chromosome to another. Inversions occur when part of the DNA sequence is reverse
complemented; for example, in Figure 2.1, the subsequence CCT is first reversed to TCC
and then complemented to AGG. The complement for the base A is T and vice versa, and
the complement for the base C is G and vice versa.
Copy number variation (CNV) is a type of structural variation where the number
of copies in a DNA region varies among the population and involves thousands of
nucleotides. There are two types of CNV: duplication and deletion. Duplication is where
a one kilobase or more is repeated, and deletion is where one kilobase or more is lost
from the DNA sequence.
For cancer risk predictions, there are different genomic-based data that can be
used such as Polygenic Risk Scores (PRS) [20-22], DNA variants identified through
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Genome-Wide Association Studies (GWAS) [23, 24], genomic variants detected by SNP
arrays, and variants discovered from Next Generation Sequencing (NGS) data [25].

2.1 Polygenic Risk Score (PRS)
Polygenic Risk Score (PRS) is a continuous variable that is calculated from an ensemble
of known markers for the disease of interest, which are obtained from published (GWAS)
findings, one way to construct the PRS feature is to count the number of the known risk
alleles present in each sample. Another way is to calculate the risk alleles and assign a
weight specifically to each risk allele [26]. Many studies attempt to use PRS to estimate
breast cancer risk in high-risk women [27-29]. In [27], the authors found that including
PRS from known breast cancer SNPs have improved cancer risk prediction in high-risk
women when compared to family history alone [26].

2.2 Genome-Wide Association Studies (GWAS)
The goal of GWAS is to interrogate human genome variation to identify statistically
significant variations that differentiate large cohort of cases (individuals with the disease
present) from controls (disease-free individuals) [30]. A common measure of the effect
size of the association between a given SNP and a particular disease in GWAS is the odds
ratio (OR). For example, in a biallelic SNP, which have only two possible bases, for the
two allele copies in the DNA there are three unordered possible genotypes A/A, A/a, or
a/a, where the letter ‘A’ represents the major allele and the letter ‘a’ represents the minor
allele (less frequent allele). Table 2.1 gives an example of calculating alleles at a
particular SNP for case and control groups in a 2X2 contingency table.

7

Table 2.1 Dominant Genotypic Model 2x2 Contingency Table

Disease (cases)
Healthy (controls)
Total

A/A or A/a
e

a/a
f

Total
r1 = e+f

g

h

r2 = g+h

c1 = e+g

c2 = f+h

t = (r1+r2+c1+c2)

The odds ratio under the dominant model is then calculated from Table 2.1 as:

!"($/$) () ($/*) =

,×ℎ
/×0

(2.1)

To compute odds ratio or chi-squared statistic in a given SNP for cases and
controls, there are different models to group the genotypes into two classes (2x2) instead
of having a 2x3 table for genotypes ‘a/a’, ‘A/a’, and ‘A/A’. These models are additive,
multiplicative, recessive, and dominant.
To calculate the odds ratio under a dominant model for ‘A’, the model assumes
that having an ‘A’ increases the risk and for recessive model vice versa, one needs to
compute the odds of disease given that an individual carries an ‘A’ genotype and the odds
of disease giving that an individual carries an ‘a/a’ genotype, then takes the ratio of the
two odds. In Equation 2.1, if the OR is greater than one, then the ‘A’ genotype increases
the risk of the disease. If the OR is less than one, then having a genotype of ‘A’ decreases
a person’s risk of having the disease. However, if the OR is equal to one, then there is no
association between the genotype and the disease. The chi-squared test is a standard test
used in GWAS for calculating the statistical significance of a genotype, assuming a
dominant/recessive model, for a particular disease. From Table 2.1, the chi-squared can
be calculated, with a degree of freedom = 1 as:
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12,4 =
9

52 74
× ×6
6 6

9

Χ9 = : :
2>? 4>?

(2.2)

9

(2.3)

;!2,4 − 12,4 =
12,4

Where !2,4 is the observed count in each cell in Table 2.1 for cases and controls, and 12,4
is the expected count for each cell under independence assumption.
Many genome-wide association studies (case and control) have singled out SNPs
and genes that are individually significant for gliomas [31-33]. Other studies identified
several SNPs that are strongly associated with kidney renal clear cell carcinoma (KIRC)
[34], cervical kidney renal papillary cell carcinoma (KIRP) [35], and chronic
lymphocytic leukemia (CLL) [36].
GWA studies have identified many susceptibility loci for many cancers, but these
novel variants cover only a small portion of the genome. Variants called from Next
Generation Sequencing or SNPs array data have higher genome coverage, and therefore,
there is a need to exploit these collective SNP data to assess its cancer risk predictive
ability using machine learning methods.

2.3 SNP Array
An SNP array is a chip-based microarray technology offered primarily by Affymetrix and
Illumina companies. Affymetrix genome-wide human SNP array 6.0 has 906,600 probes
to genotype SNPs. The array is composed of hundreds of thousands of probes on a glass.
Each probe contains multiple fixed short single-strand complement sequences for specific
locus in the DNA sequence that binds to specific target sequence fragments (the ones
9

from the sample) and produces an intensity value for each allele. If two allele intensities
have the same values, then the sample is heterozygous, which means the individual
carries two different allele at that locus.
The dissertation analyzes Affymetrix arrays from CEL files, which are
Affymetrix file format, raw data containing intensity values of the individual probes and
locations for the hybridized array, after the array scan finishes [37]. In Chapter 3, the
dissertation compares linear SVM classification accuracy in chronic lymphocytic
leukemia (CLL) cases and controls with Affymetrix SNP array variants versus variants
obtained from whole-exome sequencing (WES). The research obtained 232 samples’
CEL files (for case and control samples) from the National Institute of Health (NIH)
database of Genotypes and Phenotypes (dbGaP) portal and SNPs that are discovered with
next-generation sequencing and genome analysis toolkit (GATK) [38, 39] of the same
samples set. The dissertation uses Affymetrix Genotyping Console software to create
samples genotype calls.
Affymetrix Genotyping software employs the Birdseed algorithm, which makes a
multi-chip analysis to estimate a signal intensity of each SNP’s allele, to make a genotype
call, the algorithm fits a gaussian mixture model in two-dimensional A-signal vs. Bsignal space [40]. The Birdseed algorithm assigns a confidence score for each genotype
call between 0 and 1, where 0 is the highest quality, and 1 is the lowest [41]. The
dissertation uses the program default contrast quality control threshold ≥ 0.4 for each
sample.
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2.4 Next Generation Sequencing (NGS) Variants Discovery
NGS technology allows faster and cheaper sequencing of human genomes than Sanger
sequencing. The NGS technology sequences millions of short DNA fragments in parallel,
and can sequence the whole-genome, or only whole-exome (coding regions). After
obtaining the short reads from the sequencing machine, it needs to be mapped to a
reference genome using alignment software like Burrows-Wheeler aligner (BWA),
Bowtie, or Tophat. Once the short reads are mapped. A BAM/SAM file will be generated
and used for downstream variants discovery analysis tools like GATK and SAMtools.
Cancer predictive ability depends on the cancer primary site with some cancers
are more likely to be caused by germline mutations. For example, breast cancer is
associated with mutations in gene BRCA1 and BRCA2. Therefore, it is expected to
achieve higher prediction accuracy in some cancers, and low on others [42].
Many genomic variations are due to ancestry and geographical location of
individuals [43]. Studies were able to determine the geographical origin of people based
on their genetic makeup with high accuracy [43, 44]. Therefore, to build a model for
cancer predication based on genetic variation, it is better to include specific individuals
with common ethnicity and race.
Genomic factors are not the sole cause of most cancers. In fact, 90% of cancers
are caused by somatic mutations, non-inherited changes in the DNA sequence, that are
triggered by combination of contributing factors such as environmental, lifestyle, and
genomic predisposition [42].
Recent studies suggest that some cancers share genetic mutation causes [45, 46].
Figure 2.2 shows the most closely correlated cancers and their P-values [46]. Shared
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heritability among some cancers makes it theoretically possible to learn on one cancer
and predict on related rare cancer. In Chapter 3, the dissertation explores the ability of
generalizing predictive model learned on CLL and to predict lymphoma, and head and
neck cancers. In Chapter 4 the dissertation preforms a cross-study where it learns a
predictive model in one kidney subtype and predicts unseen samples from another kidney
subtype.

Figure 2.2 Cancer primary sites correlation; dots denote P < .01.
Source: [46]
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CHAPTER 3
CROSS-VALIDATION AND CROSS-STUDY VALIDATION OF CHRONIC
LYMPHOCYTIC LEUKAEMIA WITH EXOME SEQUENCES AND MACHINE
LEARNING
3.1 Introduction
In the last few years, there have been many studies exploring disease risk prediction with
machine learning methods and genome-wide association studies (GWAS) [47-56]. This
includes various cancers and common diseases [57-61]. Most studies employ a two-fold
machine learning approach. First, they identify variants from a set of training individuals
that consist of both case and controls. This is usually a set of single nucleotide
polymorphisms (SNPs) that pass a significance test, or a number of top-ranked SNPs
given by a univariate ranking method. In the second part they learn a model with the
reduced set of variants on the training data and predict the case and control of a validation
set of individuals.
For diseases of low and moderate frequency, SNPs have been shown to be more
accurate than family history under a theoretical model of prediction [62]. However, for
diseases with high frequency and heritability family history-based models perform better
[62]. Clinical factors with SNPs yield an area under curve (AUC) of 0.8 in a Japanese
type 2 diabetes dataset but their SNPs have a marginal contribution of 0.01 to the
accuracy [63]. With a large sample size, the highest known AUC of 0.86 and 0.82 for
Crohn’s disease and ulcerative colitis were reported [64]. There the authors contend this
may be a peak or considerably larger sample sizes would be needed for higher AUCs.
Bootstrap methods have given AUCs of 0.82 and 0.83 for type 2 diabetes and bipolar
disease on the Wellcome Trust Case Control Consortium (2007) datasets, considerably
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higher than previous studies. Some studies have also used interacting SNPs in GWAS to
boost risk prediction accuracy [65, 66].
Many of these studies are cross-validation studies. They split the original dataset
into training and validation several times randomly and for each split predict case and
controls in the validation. Recent work has shown that this may not necessarily generalize
to data from different studies [67]. Thus, in any risk prediction study it is now essential to
include cross-study validation on an independent dataset.
While continuing efforts are made to improve risk prediction accuracy with
GWAS datasets, the AUCs are still below clinical risk prediction particularly for cancer.
The reasons posed for this failure include lack of rare variants, insufficient sample size,
and low coverage (.1% of the genome sequenced) [68-70]. In this study, we detect
variants from whole exome data that has a much larger coverage. We seek to determine
the cross-validation and cross-study prediction accuracy achieved with variants detected
in whole exome data and a machine learning pipeline.
The study obtained a chronic lymphocytic leukemia 140X coverage whole exome
dataset [71] [72] of 186 tumor and 169 matched germline controls from the NIH dbGaP
[73]. The whole exome dataset is composed of short next generation sequence reads of
exomes as shown in Figure 3.1. This is one of the largest datasets available, and is an
adult leukemia with an onset median age of 70 [74]. There is currently no known early
SNP based detection test for this cancer. Current tests include physical exam, family
history, blood count, and other tests given by the National Cancer Institute (see
http://www. cancer.gov/cancertopics/pdq/treatment/cll/patient).
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Figure 3.1 Whole-exome sequences are short reads of exomes obtained by next
generation sequencing.
Short read exome sequences were mapped to the human genome reference
GRCh37 with the popular Burrows-Wheeler aligner (BWA) [75] a short read alignment
program. This research then used the genome analysis toolkit (GATK) [38, 39, 76] and
the Broad Institute exome capture kit (bundle 2.8 b37) in a rigorous quality control
procedure to obtain SNP and InDel variants. Cases and controls that contained excessive
missing variants were excluded, and in the end 122,392 SNPs and 2200 InDels across
153 cases and 144 controls were obtained.
To better understand the risk prediction value of these variants, the research
performs a cross-validation technique on the total 153 cases and 144 controls by creating
random training validation splits. Then the dissertation compares the same crossvalidation accuracy to that on an Affymetrix 6.0 panel genome wide association study for
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the same subjects to see the improvement given by the exome analysis. The study
obtained exome sequences from three different studies from dbGaP for independent
external validation (also known as cross-study validation; [67]). The study ranked SNPs
in training set with the Pearson correlation coefficient [77] and predicted labels of cases
and controls with the support vector machine classifier in an external validation dataset.
The research studied the biological significance of top Pearson ranked SNPs in the data.

3.2 Materials and Methods
Rigorous analysis on raw exome sequences was performed. First, sequences were
mapped to the human genome and variants obtained. Then variants were encoded into
integers to create feature vectors for each case and control sample.
3.2.1 Whole Exome Sequencing Data and Human Genome Reference
Whole exome sequences of 169 chronic lymphocytic leukemia patients [71, 72] was
obtained from the NIH dbGaP website [73] with dbGaP study ID phs000435.v2.p1. Each
of the 169 patients has matched tumor-normal sequencing data. In addition, exome tumor
sequences of 17 patients were obtained from dbGaP after publication of the original study
[71, 72]. This gives a total of 186 cases and 169 controls. The ancestry of the patients is
not given in the publications or in the dbGaP files except that we know they were
obtained from the Dana Farber Cancer Institute in Boston, Massachusetts, USA. The data
comprises of 76 base pair (bp) paired-end reads produced by Illumina Genome Analyzer
II and Hiseq2000 machines and the Agilent SureSelect capture kit by the Broad Institute
[71]. The data was sequenced to obtain mean coverage of approximately 140X.
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The research uses the human genome reference sequence version GRCh37.p13
from the Genome Reference Consortium (http://www.ncbi.nlm.nih.gov/projects/genome/
assembly/grc/). At the time of doing this experiment, version 38 of the human genome
sequence was introduced. However, the mapping process was started well before its
release and demanded considerable computational resources. Therefore, this work
continued the analysis with version 37.
3.2.2 Next Generation Sequencing Analysis Pipeline
The pipeline includes mapping short reads to the reference genome, post processing of
alignment, variant calling, and filtering candidate variants. The total exome data was in
approximately 3 Terabytes (TB) and required high performance computing infrastructure
to process. Perl and various bioinformatics tools were used to automate the analysis
pipeline.
Mapping Reads: As a first step, exome short read sequences of 186 tumor cases and
169 matched germline controls were mapped to the human genome reference GRCh37
with the BWA MEM program [75]. Six cases and 14 controls were excluded due to
excessively large dataset size and downloading problems, and reads with mapping quality
(MAPQ) below 15 were removed.
The read mapping is a process where short read DNA sequences mapped to a
reference genome. There are many different programs available for this task, and each
one differs in mapping methodology, accuracy, and speed. This pipeline uses the popular
program BWA MEM program (version 0.7a-r405) [75] that implements the BurrowsWheeler transform. BWA MEM is relatively accurate for its fast processing speed while
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mapping against vast reference genome such as humans [78, 79]. Default parameters
were used for mapping reads to the human reference genome.
BWA MEM produces its output in a standard format called Sequence Alignment Map
(SAM). SAMtools version 0.1.18 [75] were used for further analysis of the SAM output
files. Each alignment in SAM format was converted into its binary format (BAM),
alignments were sorted with respect to their chromosomal position, and then indexed.
SAMtools were used to generate mapping statistics and merging alignments of the same
patient

across

different

files.

PICARD

tool

(version

1.8,

http://broad

institute.github.io/picard/) were used to add read groups, which connects the reads to the
patient subject. The pipeline removed duplicates reads introduced by the PCR
amplification process to avoid artifacts using the PICARD MarkDuplicates program.
Finally, using SAMtools, unmapped reads and the ones with mapping score (given in the
MAPQ SAM field) smaller than 15 were removed.
Variants Detection: GATK [38, 39, 76] version 3.2-2 with the Broad Institute exome
capture kit (bundle 2.8 b37 available from ftp://ftp.broadinstitute.org/) was used to detect
SNPs and InDels in the alignments. These SNPs and InDels are referred to as variants.
These variants pass a series of rigorous statistical tests [39, 76]. If a variant does not pass
the quality control or no high-quality alignment of a read to the genome was found in that
region, then GATK reports a missing value.
The analysis found 38 individuals that contain at least 10% missing values. These
samples were removed from the data and variants recomputed for the remaining 153
cases and 144 controls again with GATK and the exome capture kit. The study also
removes all variants that have at least one missing value, and so eliminate the need for
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imputation. Note that if these variant features with missing values were removed before
the 38 individual samples with many missing values, it going to generate just a few
variants with limited predictive value.
The variant detection procedure gave a total of 122392 SNPs and 2200 InDels.
These variants were then encoded into integers thus obtaining feature vectors for each
case and control. Figure 3.2 shows the encoding process to get integer values for variant
features.

Figure 3.2 Encoding of SNPs and InDels into 0,1 and 2 integers. GATK program [39]
identifies homozygous and heterozygous genotypes when there is a mutation or insertion
deletion. For individuals where a SNP is not reported but found in a different individual,
the study uses a value of 0.
3.2.3 Machine Learning Pipeline
After completing the variant analysis in the previous step, the study proceeds with the
machine learning analysis. Machine learning methods are widely used to learn models
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from classified data to make predictions on unclassified data. They consider each data
item as a vector in the space of dimension given by the number of features. In this study,
each data item is a case or control set of exome sequences. By mapping each set to the
human genome, variants were obtained, which represent features. Thus, the number of
variants determines the number of dimensions in the feature space.
Data Encoding: Since the input to machine learning programs must be feature vectors,
each SNP and InDel converted into an integer. The variants reported by GATK are in
standard genotype form A/B where both A and B denote the two alleles found in the
individual. The GATK output is in VCF file format whose specifications (available from
http://samtools.gith ub.io/hts-specs/VCFv4.1.pdf) provide details on the reported
genotypes. When A = 0 this denotes the allele in the reference. Other values of 1 through
6 denote alternate alleles and gaps. The study kept the max alternative allele option to six,
which is also the default value in GATK. The pipeline performs the encoding 7 A + B to
represent all possible outputs.
Each feature vector represents variants from a human individual and is labeled –1
for a case and +1 for a control. The labels +1 and –1 are standard in the machine learning
literature [80].
Feature Selection: The research ranks the features with the Pearson correlation
coefficient (PCC) [77].

ABB =

∑G2(D2,4 − D4,EF*G )(H2 − HEF*G )
9

I∑G2;D2,4 − D4,EF*G = I∑G2;H2, − HEF*G =

(3.1)
9

where D2,4 represents the encoded value of the JKL variant in the M KL individual and H2 is
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the label (+1 for a case and –1 for a control) of the M KL individual. The Pearson correlation
ranges between +1 and –1 where the extremes denote perfect linear correlation and 0
indicates none. The study ranks the features by the absolute value of the Pearson
correlation.
Classifier: The pipeline uses the popular soft margin support vector machine (SVM)
method [81] implemented in the SVM-light program [82] to train and classify a given set
of feature vectors created with the above encoding. In brief, the SVM finds the optimally
separating hyperplane between feature vectors of two classes (case and control in our
case) that minimizes the complexity of the classifier plus a regularization parameter C
times error on the training data. For all experiments, the pipeline uses the default
regularization parameter given by:

B=

1
∑G2 D2O D2

(3.2)

where n is the number of vectors in the input training (case and control individuals in this
study) and D2 is the feature vector of the M KL individual [82], in other words, the C is the
inverse of the average squared length of feature vectors in the data.
Measure of Accuracy: We define the classification accuracy as 1-BER, where BER is
the balanced error rate [83]. The balanced error is the average misclassification rate
across each class and ranges between 0 and 1. For example, suppose class case has 10
individuals, and class control has 100. If the pipeline incorrectly predicted 3 cases and 10
controls, then the balanced error is:
3
10
P10 + 100T
= 0.2
2
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(3.3)

3.2.4 High Performance Computing
The research uses the Kong computing cluster and the condor distributed computing
system at NJIT to speed up the computation.

3.3 Results
Next-generation sequencing pipeline and data encoding give feature vectors each
representing a case or control sample and each dimension representing an SNP or InDel
variant. The study employs a machine learning procedure to understand the predictive
value of the variants.
3.3.1 Cross-Validation
Cross-validation is a standard approach to evaluate the accuracy of a classifier from a
given dataset [80]. The pipeline randomly shuffles the feature vectors and picks 50% for
training and leaves the remaining for validation. On the training, the study ranks the
variants with the Pearson correlation coefficient. This step is key to performing feature
selection in a cross-validation study. Alternatively, one may perform feature selection on
the whole dataset and then split it into 50% training. However, this method is unrealistic
because in practice test labels are not available. In the cross-validation study simulates
that setting by using a validation dataset in place of the test data. The validation labels are
only to evaluate the accuracy of the classifier and should not be used for any model
training, including feature selection. Some studies make this mistake (as previously
identified; [84], but here the pipeline performs all SNP selection only on the training data.
The pipeline then learns a support vector machine [81] with the SVM-light
software [82] and default regularization on the training set with k top-ranked SNPs (see
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Figure 3.3). This study considers increments of ten variants up to 100 and increments of
100 up to 1000. Thus, the values of k=10, 20, 30, ..., 100, 200, ...,1000. For each value of
k, this experiment predicts the case and control status of the validation samples and
record the accuracy. The pipeline repeats this for 100 random splits and graph the
average with standard deviations.

Figure 3.3 Illustration of cross-validation technique.
Figure 3.4 shows the mean cross-validation accuracy of the support vector
machine on 50% training data across 100 random splits. It shows that InDels alone have
much poorer accuracy than SNPs alone and contribute marginally to the SNPs. This
experiment achieved a top accuracy of about 82% with the top 20 SNPs. The accuracy
drops after the top 20 SNPs threshold.
Accuracies shown in Figure 3.4 are averaged across 100 training validation splits.
In each split, this study first ranks the SNPs and compute prediction on validation with
top k ranked ones. There is no one set of 20 SNPs to be identified recall that the
accuracies shown in Figure 3.4 are averaged across 100 training validation splits. In each
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split, the pipeline first ranks the SNPs and computes prediction on validation with top k
ranked ones. Thus, there is no one set of 20 SNPs to be identified here, and this is
certainly not the same as the top 20 SNPs from the ranking on the full dataset (although
there are some in common with top-ranked ones from different splits). Alternatively, one
may consider the intersection of the top 20 SNPs from all 100 split and use them for
prediction on an independent external dataset. The drawback here is that not all of the
SNPs in the intersection may pass the GATK quality control filtering thresholds. This is
why this research ranks SNPs on the full dataset and considers the first top 100 that are
found in the external dataset.

Figure 3.4 Average cross-validation accuracy of support vector machine with top
Pearson ranked SNPs and InDels together and separately on 100 50:50 training validation
splits. Error bars indicate the standard deviation.
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3.3.2 Comparison to Cross-Validation on GWAS
To better understand the cross-validation results from SNPs obtained in the whole-exome
sequencing analysis, this study examines a GWAS for the same subjects. This is an
Affymetrix 6.0 genome-wide human SNP array of the same disease and subjects that
have been obtained from the dbGaP site for the whole exome study. The study first
removes SNPs with more than 10% missing entries and excludes samples that do not pass
the quality control test with 0.4 threshold in the Affymetrix Genotyping Console. The
quality control test measures the differences in contrast distributions for homozygote and
heterozygote genotypes in each cel file. Following this, the research ranks the SNPs with
the Pearson correlation coefficient. Then creates one hundred random 50:50 train and
validation splits and determines the average prediction accuracy of the support vector
machine in the same manner as described above for the whole-exome sequencing study.
Figure 3.5 shows that the GWAS SNPs give the highest prediction accuracy of
57% in the top 10 SNPs, but then it gradually decreases. Thus, the SNPs given by the
whole exome analysis, which yields higher prediction accuracy, may serve as better
markers that are not found in the GWAS. Upon closer examination, one sees that there is
no overlap between the top 1000 ranked SNPs from the exome sequencing and GWAS
datasets except for the four that have low Pearson correlation values.
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Figure 3.5 Average cross-validation accuracy of support vector machine with top
Pearson ranked SNPs on 100 50:50 training validation splits of the GWAS dataset.
3.3.3 Cross-Study Validation
For cross-study validation on an independent dataset the pipeline considers a lymphoma
whole exome study that has case subjects for lymphocytic leukemia as well as a few
controls. This research considers controls from a head and neck cancer and a breast
cancer study.
•

Eighteen cases and three controls from a lymphoma whole exome study with
dbGaP study ID phs000328.v2.p1 [85]. Reads are 101bp length produced from
Illumina HiSeq 2000 machine and have 3.4X coverage. The ancestry or origins of
data in this study are unavailable in the publication and the dbGaP site.

•

Three controls from neck and head cancer whole exome study with dbGaP study
ID phs000328.v2.p1 [86]. Reads are 77bp length produced from Illumina HiSeq
2000 and have 6.9X coverage. Individuals in this study are from the University of
Pittsburgh Head and Neck Spore neoplasm virtual repository.

•

Seven controls from breast cancer whole exome study with dbGaP study
phs000369.v1.p1 ID [87]. Reads are 77bp length produced from Illumina HiSeq
2000 of coverage 5.9X. Individuals in this study have Mexican and Vietnamese
ancestry.

In all three datasets, this research follows a similar procedure that used for the chronic
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lymphocytic leukemia exome dataset. The pipeline maps the short reads to the human
genome with the BWA program and detects variants with GATK using the same software
and parameters as for the lymphocytic leukemia dataset.
Since this is a validation dataset, one cannot use the labels to perform any feature
selection or model training. Instead, one learns the support vector machine model from
the full original dataset. The study refers to that as the training set here. The study does
not consider all SNPs from the training dataset to build a model. First, the study obtains
the top 1000 Pearson correlation coefficient ranked SNPs in the full training. Many of
these SNPs do not pass the GATK quality control tests on some of the external validation
samples. One reason for this is the much lower coverage (<10X) of the external datasets.
Amongst the ones that were detected, this research considers just the top 100 ranked
ones. For each top k ranked ones (for k =10,20,30,...,100), the research learns a support
vector machine model on the training and uses it to predict labels of the validation data.
As previously discussed, the top k ranked SNPs here are not the same as the top k ranked
SNPs in the earlier cross-validation study.
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Figure 3.6 Accuracy of support vector machine with top Pearson ranked SNPs on just
the external independent samples. Since this is a validation dataset one cannot uses the
labels for any type of model training including ranking of features. Thus, the ranking of
SNPs is obtained from the original full dataset.
Figure 3.6 shows that only the top-ranked SNPs give prediction accuracy above
0.5. The study examines the number of cases and controls predicted correctly by the top
20 ranked SNPs in Table 3.1. Note that the imbalanced accuracy from the table is 64.5%.
However, this research uses the balanced accuracy that accounts for different sizes of
each class, and that value, which is plotted in Figure 3.6, is 69.4%. Table 3.1 shows that
the controls for the head and neck cancer are correctly predicted. In the lymphoma
dataset also, all controls are correctly classified, but more than half cases are incorrectly
classified as controls.
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Table 3.1 Number of Correctly Predicted Case and Controls in Three External Datasets
Study
Lymphoma

Cases
18

Controls
3

Correct cases
7

Correct controls
3

Head and neck cancer

0

3

0

3

Breast cancer

0

7

0

7

3.3.4 Biological Significance of Top Tanked SNPs
The study considers the top 200 ranked SNPs in the Pearson correlation ranking of all
SNPs in the full dataset. Those variants were fed to the popular ANNOVAR program
[88] to determine genes and genomic regions they lie on.
The study founds SNPs in genes SF3B1 and MYD88 both of which were reported
as significant genes in the original study of the dataset [71]. It also founds SNPs in genes
STRN4 and HLA-DRB5 both of which have been shown to be previously associated with
this disease in genome wide association studies [89-92] . Table 3.2 provides additional
details of the SNPs in these genes. All four are exonic but don’t necessarily rank high in
Pearson correlation coefficient.

Table 3.2 Variants Found in Genes Previously Known to be Associated with CLL
Pearson
0.19

Chr
19

Pos
47230736

Rank
93

Region
Exonic

Gene
STRN4

Ref
G

Alt
T

Type
Hom

0.19

3

38182641

98

Exonic

MYD88

T

C

Hom

0.19

2

198266834

98

Exonic

SF3B1

T

C

Hom

0.17

6

32497985

159

Exonic

HLA-

A

G

Hom

DRB5
Note: The first column gives the Pearson correlation coefficient value, followed by chromosome number,
position in chromosome, SNP rank given by the Pearson correlation coefficient, genomic region, gene,
reference nucleotide, alternate nucleotide, and the type.
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The research also provides the SNPs information from the top three high-ranking
genes in Table 3.3. There it shows that the Pearson correlation of the top ranked SNPs is
considerably higher than the SNPs in known genes identified above. While their direct
association with lymphocytic leukemia is unknown, they are well implicated in many
different cancers. The highest rank is the Aminoacyl tRNA synthetases (AARS) gene that
is known to be associated with various cancers [93]. Following this is the valyl-tRNA
synthetase (VARS) gene that is also known to be associated with cancer [94]. The WD
repeat domain 89 (WDR89) is associated with many cancers as given by the Human
Protein Atlas (http://www.proteinatlas.org/ENSG00000140006-WDR89/cancer) and The
Cancer Network Galaxy (http://tcng.hgc.jp/index.html?t=gene id=112840).

Table 3.3 Details of Top-Ranking Variants on the Full Dataset
Pearson
0.72

Chr
16

Pos
70305806

Rank
1

Region
Gene
Exone AARS

Ref
G

Alt
A

Type
Hom

0.71

16

70305809

2

Exone

AARS

G

A

Hom

0.59

16

70305812

3

Exone

AARS

C

A

Hom

0.36

6

31749930

5

Exone

VARS

C

G

Hom

0.33

14

64066352

9

Exone

WDR89

T

A

Hom

Table 3.4 lists top ranking SNPs from the GWAS with previous association to this
disease and that lie on known genes. Some of these genes are previously linked to
leukemia. For example, EML1 [95], KDM4C [96], NEBL [97], BNC2 [98], and ANO10
[99] are all known to be associated with leukemia while RGS20 and ZNF25 are known to
be expressed in leukemia. However, none of the top 1000 ranked SNPs in the GWAS
overlap with the ones from the exome study except for four that lie far down in the
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rankings.

Table 3.4 Details of Top-Ranking Variants on the GWAS Dataset
dbSNP ID
rs1951574

Pearson
0.33

Chr
14

Pos
100346664

Rank
4

Gene
EML1

rs1905359

0.33

8

54851272

5

RGS20

rs2792228

0.32

9

6976680

6

KDM4C

rs11011415

0.31

10

38264389

7

ZNF25

rs3900922

0.31

10

21287528

8

NEBL

rs3739714

0.31

9

16435848

9

BNC2

rs9844641

0.31

3

43476335

10

ANO10

3.4 Discussion
In addition to the results shown here two variations were explored in the machine
learning pipeline to see if they would increase prediction accuracy. First, the study looked
at a naive encoding where it converts homozygous alleles to 0 and 2 and the
heterozygous to 1. This marginally lowered the accuracy. Second, the research
considered the chi-square ranking of SNPs instead of Pearson correlation and this also
marginally lowered the accuracy.
One main challenge in this study is the size of the training set that is considerably
smaller than sample sizes (of several thousand) used in GWAS based risk prediction
studies. The primary source of data is the NIH dbGaP repository and so the sample sizes
are limited to the data accumulated there.
31

Another challenge is the quality and coverage of data in dbGaP. For the three
external studies, the research aimed to predict case and control of many samples. Yet for
several of the downloaded datasets coverage was insufficient and the analysis founds the
top-ranked variants only in a few samples.
Finally, differences in ancestry can affect risk prediction [100-102]. In this case
the pipeline learned a model from data obtained in patients at the Dana Farber Cancer
Institute in Boston, Massachusetts. In the three external datasets one is of Mexican and
Vietnamese ancestry whose genetics are likely to be different from patients at the Dana
Farber Institute.

3.5 Conclusion
Starting from raw exome sequences this study obtained a model for predicting chronic
lymphocytic leukemia after a rigorous next generation sequencing and machine learning
pipeline. The analysis evaluated the model in cross-validation studies as well as on three
independent external datasets as part of cross-study validation. In cross-validation, the
pipeline achieves a mean prediction of 82% compared to 57% obtained on an Affymetrix
6.0 panel genome wide association study. In the external cross-study validation, the
pipeline obtains 70% accuracy with a model learned entirely from the original dataset.
Finally, the study shows biological significance of top-ranking SNPs in the dataset. The
research shows that even with a small sample size we can obtain moderate to high
accuracy with exome sequences and is thus encouraging for future work.
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CHAPTER 4
CROSS-VALIDATION AND CROSS-STUDY VALIDATION OF KIDNEY
CANCER WITH MACHINE LEARNING AND WHOLE EXOME SEQUENCES
FROM THE NATIONAL CANCER INSTITUTE
4.1 Introduction
Cancer risk prediction from one’s DNA is of considerable interest in modern medicine
[103, 104]. One way to achieve this is to determine mutations by comparing DNA in
tumor cells to healthy ones. Such mutations are called somatic and could potentially be
used for early detection and prevention of cancer [105-107].
The majority of efforts on predicting cancer are focused on using SNPs obtained
from genome-wide association studies and from whole exome sequences [108-112].
However, there are also dangerous pitfalls associated with SNP-based cancer risk
prediction [113]. The most common one is lack of validation on an independent dataset,
also known as cross-study validation [67]. Most studies focus on the cross-validation
accuracy, which is obtained by splitting a given dataset randomly into training and
validation several times and obtaining the average accuracy on the validation. In a crossstudy validation we want to see how well SNPs determined on data for one disease from
a specific study generalizes to the same disease or a related one from a different study.
This research explores the accuracy of predicting kidney cancer case and controls
with somatic mutations across two different whole exome sequence datasets obtained
from the National Cancer Institute Genomic Data Commons database [114]. This
research considers datasets of renal papillary cell carcinoma and chromophobe renal cell
carcinoma. The data are pre-aligned short read sequences from which the pipeline
determines variants. Three quality control methods of variant detection were examined
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and the most rigorous one gives the most parsimonious model with the highest accuracy.
The important result is the cross-study validation between the two datasets, and
this experiment achieves an accuracy of 66.2% when predicting chromophobe individuals
after learning a model of ten SNPs from the renal papillary dataset. The work here
suggests that it can predict kidney chromophobe carcinoma with high quality SNPs
obtained from a kidney papillary carcinoma dataset. The following sections describe the
methods in detail followed by experimental results.

4.2 Methods
This section describes the data along with the quality control protocol used. Then it
describes the machine learning pipeline.
4.2.1 Data
There are several kidney cancer whole exome datasets at the National Cancer Institute
(NCI) Genomic Data Commons (GDC) portal from across three different projects: The
Cancer Genome Atlas (TCGA), TARGET, and Foundation Medicine Adult Cancer
Clinical Dataset (FM-AD). Authorization to the TCGA project only was obtained, and
two of the TCGA three datasets were downloaded.
•

Kidney Renal Papillary Cell Carcinoma (KIRP): total of 291 individuals.

•

Kidney Chromophobe (KICH): total of 113 individuals.
Both datasets contain individuals of European, African, and Asian ancestry, and

have older patients between cancer stages I and III. For each individual in each dataset
exome sequences of the affect cell and a healthy cell (from the same person) are made
available.
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To avoid mutations that occur from ancestry differences, only individuals of
European ancestry (which is also the majority ancestry) were considered. Due to time
constraints and checksum/download errors, only some male subjects from each study
were downloaded. Table 4.1 gives the number of case and controls that were obtained for
each study.

Table 4.1 Kidney Cancer Datasets Used in the Study
Dataset
TCGA-KIRP

Cases
110

Controls
110

TCGA-KICH

34

34

Each case and control file that was downloaded is a pre-aligned exome sequence
mapped to the human genome reference (build 38, version GRCh38.d1.vd1) with the
BWA program [75]. Thus, from the GDC portal BAM files were obtained [75] for each
individual’s tumor and healthy exome sequences. These are binary files of the SAM
format that show the alignment of each short read to the reference genome.
The NCI GDC portal also contains files with already detected variants for each
individual. However, those variants were obtained by comparing each individual’s
healthy exome sequences to their tumor ones. In this analysis, a collective analysis of all
the individuals at the same time to determine variants were performed, so it can detect
missing values as explained below.
4.2.2 Quality Control for Determining SNPs
The pipeline combines all the case and controls and performs a collective variant calling
with the popular Genome Analysis Toolkit (GATK) software [38, 39, 76]. In the

35

collective analysis, the study was able to identify SNPs that are not reported across
samples. For example, if a SNP does not pass quality control it is not reported and is thus
a missing value. The study explores three filtering methods of obtaining SNPs with the
popular Genome Analysis Toolkit (GATK) software [38, 39, 76]. By default, any reads
with a MAPQ quality score (which is a measure of the alignment quality) below 25 is
eliminated in the analysis:
•

Soft filtering: This is the GATK Variant Quality Score Recalibration, which uses
machine learning to identify good variants from bad ones.

•

Hard filtering: Any SNP with a genotype quality score below 30 and a depth
below 5 is ignored. The genotype quality score is a statistical quantity the gives us
the accuracy of the SNP and the depth is the minimum of reads that contain the
SNP. These are default values used in the GATK program.

•

Soft and hard filtering: Both of the above are applied.
After each filtering method, the pipeline removes any SNP that is missing (not

reported by GATK) in at least one sample, thus eliminating the need for imputation. After
filtering, the number of SNPs that are obtained is given in Table 4.2. The same table also
shows the number of SNPs common in the two studies, this set is used for the cross-study
validation.

Table 4.2 Total Numbers of SNPs in Datasets after Three Filtering Methods

Soft
264858

Filtering Method
Hard
131141

Soft + Hard
109700

TCGA-KICH

246290

135937

111394

Intersection of

131157

44426

36029

Dataset
TCGA-KIRP

KIRP and KICH
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4.2.3 SNP Encoding
Once a dataset of SNPs is obtained after the quality control described previously, the
pipeline performs encoding. The GATK program outputs variants in the VCF format
[115], which encodes the reference allele as 0 and alternate alleles (including gap) from 1
onwards. For example, a genotype of 0/0 means the individual is homozygous in the
reference allele, 0/2 means heterozygous in the second alternate allele, and 1/1 means
homozygous in the second alternate allele. Therefore, it can be encoded to unique
numbers with the simple formula 4A+B for a SNP encoded as A/B.
To evaluate the predictive capability of SNPs, the research performs crossvalidation and a cross-study validation experiments. In the cross-validation, the analysis
splits a given dataset into training and test and evaluates the error of predicting the test. A
high accuracy does not necessarily mean the SNPs would generalize to other datasets or
related diseases. Thus, a cross-study validation was performed to determine
generalization to another dataset.
4.2.4 Cross-Validation and Machine Learning
A step-wise cross-validation procedure is as follow:
1. First, the analysis performs 10-fold cross-validation, where data roughly divided
into ten equal parts. The first 90% set is the training data, and the remaining 10%
is the test data.
2. The pipeline ranks the SNPs according to the Pearson correlation coefficient [80]
as implemented in the Python scikit-learn machine learning library [116]. The
Pearson correlation coefficient is the sample correlation coefficient that measures
the covariance between two variables divided by their variances to normalize. A
value close to 1 or -1 indicates a linear correlation whereas 0 means the variables
are uncorrelated [80].
3. The pipeline considers the top k ranked SNPs for increasing values of k and trains
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a support vector machine (SVM) [81], a fast linear classifier with known powerful
generalization capabilities, also with the linear SVM in the Python scikit-learn
library [116]. Then cross-validate the regularization parameter C of the SVM by
cross-validating on the training set only.
4. With the trained model, the pipeline predicts cases and controls of the individuals
in the test dataset and determines the error (since their true case and control status
is known).
5. Steps 1 through 4 are repeated ten times, and then the average error is calculated.
4.2.5 Cross-Study Validation
The research aims to determine the error of predicting case and controls across two
independently obtained studies. It measures the error of a predicting case and control in
the KICH dataset, which contain individuals with renal chromophobe carcinoma, with a
model trained on the KIRP dataset, which are renal papillary carcinoma individuals.

4.3. Results
Here the results of The Cancer Genome Atlas Kidney Chromophobe (TCGA-KICH) and
The Cancer Genome Atlas Cervical Kidney renal papillary cell carcinoma (TCGA-KIRP)
datasets cross-validation are outlined.
4.3.1 Cross-Validation
Figure 4.1 shows the average accuracy of the support vector across 10-fold crossvalidation of the KIRP dataset. The research makes several interesting observations
consistent with previous findings.
•

Top ranked SNPs with the Pearson correlation coefficient give a higher accuracy
than lower ranked ones and all SNPs. This is consistent with previous findings on
predicting cancer and disease risk with genomic SNPs [50, 109, 110].

•

The soft filtering gives a slightly higher accuracy (reaching 0.76 with 500 SNPs)
and fluctuating curve compared to hard and combined filtering.
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•

The hard and combined filtering achieve their top accuracies of 0.72 and 0.71
with just top 20 and 10 ranked SNPs respectively.

•

The combined filtering gives us the most parsimonious model; it achieves its
highest accuracy with the fewest number of SNPs (10).

(a) Soft filtering

(b) Hard filtering

(c) Soft and hard filtering combined
Figure 4.1 KIRP data three filtering average CV accuracy of SVM on top ranked SNPs.
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(a) Soft filtering

(b) Hard filtering

(c) Soft and hard filtering combined
Figure 4.2 KICH data three filtering average CV accuracy of SVM on top ranked SNPs.
Figure 4.2 depicts the average accuracy of the support vector across 10-fold crossvalidation of the KICH dataset. This dataset is less than one third the size of the KIRP
dataset, and so it shows different trends. Due to its small sample size, the accuracy
fluctuates in all three filtering and peaks equally with a few and many SNPs. This dataset
is used primarily as an independent set.
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(b) Hard filtering

(a) Soft filtering

(c) Soft and hard filtering combined
Figure 4.3 Accuracy of support vector machine on the KICH dataset after trained on top
ranked SNPs in the KIRP dataset.
4.3.2 Cross-Study Validation
For the cross-study validation, the pipeline learns a support vector machine model on the
top-ranked SNPs in the KIRP dataset and predicts individuals in the KICH dataset. Figure
4.3 illustrates that the most parsimonious model is given by the soft and hard filtering.
There, the accuracy obtained is 0.66 with just 10 SNPs. In comparison the hard filtering
peaks at 0.63 with 10 SNPs and soft peaks at 0.7 with 100,000 SNPs.
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Table 4.3 Top Ten Ranked SNPs Used in the Cross-Study (Soft+Hard Filtering)
SNP
1

Ref
A

Alt
G,C

Pearson
0.35

Gene/Region
ANO2

Chromosome
12

2

A

C

0.07

ADAMTS9

3

3

G

A

0.07

Non-coding

4

A

C

0.07

GORAB

1

5

T

C

0.06

NR2C2

3

6

G

A

0.06

SELP

1

7

A

T

0.06

Non-coding

8

C

T

0.06

LOC100421093

6

9

A

C

0.06

C9orf71

9

10

G

A

0.06

FBXL4

6

While the focus is on the cross-study prediction accuracy, Table 4.3 shows the top
10 ranked SNPs in the cross- study validation. These SNPs are present in both studies,
but the ranking is performed on just the KIRP (training) dataset. Most of the SNPs are in
coding regions except for two. The SNP in the ANO2 gene has the highest Pearson
correlation whereas the others are lower by a large margin. The same SNP is also highly
ranked in both of the datasets separately.
The ANO2 gene belongs to the family of anoctamins that are known to be
expressed in gastrointestinal stromal tumors and neck and head carcinoma [117]. This
gene is known to have a functional role in calcium activated chloride currents [118] but it
is unclear how that relates kidney cancer. The ANO1 gene that comes from the same
family, however, is known to be expressed in pancreatic cancer [119].
4.3.3 Ranking of Previously Known Kidney Cancer Genes
Table 4.4 shows the ranking of SNPs present in genes previously known to be associated
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with kidney cancer [120]. It shows the rankings as well as the Pearson correlation
coefficients in the KIRP and KICH datasets separately and the intersection of their SNPs
(as in the cross-study). The MET gene is the highest ranked in the KIRP study in this
dataset, and is also a drug target for clinical treatment of renal papillary carcinoma [121].
It shows that these genes have low Pearson correlation coefficients indicating that while
they are associated with kidney cancer from previous studies their predictive value is
limited here.

Table 4.4 Rank of SNPs (PCC) Hard+Soft Filtering in Known Kidney Cancer Genes
Gene
VHL

KIRP
28296 (5.39e-18)

KICH
58117 (1.026e-17)

KIRP and KICH
15831 (5.39e-18)

FH

107511 (0)

6437 (0.07)

35682 (0)

FLCN

15889 (1.88e-17)

2777 (0.096)

13308 (7.26e-18)

MET

1975 (0.026)

20909 (3.86e-17)

799 (0.026)

TSC1

5732 (0.009)

4327 (0.088)

7430 (2.05e-17)

TSC2

16060 (1.85e-17)

4295 (0.088)

7816 (1.85e-17)

4.4 Conclusion and Future Work
The pipeline performs an initial cross-validation and cross-study validation across two
kidney cancer datasets obtained from the NCI GDC database. The results show that it can
predict kidney chromophobe carcinoma case and controls with 66% accuracy with SNPs
learned from a kidney papillary cell carcinoma dataset. More samples from the existing
datasets and other datasets from the NCI GDC database is needed to confirm the
predictive ability of SNPs in kidney cancer.
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CHAPTER 5
MACHINE LEARNING BASED PREDICTION OF GLIOMAS WITH
GERMLINE MUTATIONS OBTAINED FROM WHOLE EXOME SEQUENCES
FROM TCGA AND 1000 GENOMES PROJECT
5.1 Introduction
Estimating susceptibility to cancer from germline variants is important for recommending
regular screening that helps in early cancer detection and enhances patient chances of
successful treatment. Linkage analysis studies show that gliomas may cluster within
families [122-125]. Also, many genome-wide association studies have identified
germline genomic loci that increase glioma risk [7, 126, 127].
This work looks into the collective germline SNPs predictive ability for brain
cancer predisposition. The research preforms a Genome Analysis Toolkit (GATK) joint
germline SNPs discovery workflow for TCGA Glioblastoma Multiforme (GBM) and
Lower-Grade Glioma (LGG) white individual cases and 1000 Genomes Project white
individual controls. The SNPs that failed GATK Variant Quality Score Recalibration soft
filtering or hard filtering (genotype quality ≤ 20, depth ≤ 5, or missing genotype) quality
control were discarded from further machine learning analysis.
On the training set, SNPs with zero variance were excluded and each SNP is
scaled so that it remains between zero and one. Then, the best K SNPs were selected
based on chi-squared test value. For cross-validation, 1000 Genomes Project, GBM, and
LGG samples and their common SNPs were combined. The data were split into 10-fold
(90% for training and 10% for testing) and a predictive model was learned with SVM and
random forest classifiers. In each training fold, SVM C hyperparameters and the number
of trees to grow for RF were cross-validated with 3-fold for each top K selected SNPs.
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Then the predictive ability with average balanced accuracy across all folds were
measured. For cross-study, the research ran linear SVM on best K selected SNPs on 50%
randomly selected samples from 1000 Genomes Project and GBM and predicted LGG
and the remaining half of the 1000 Genomes Project samples.
To confirm that all samples came from the same population, principal component
analysis (PCA) was performed on the entire dataset (before feature selection), and the
first two principal components were projected. Figure 5.3 shows that the two datasets
(case and controls) are related. This step is done to confirm that the cases and controls are
not separable to limit the effect of ethnicity differences on cases and control
classification. SNPs departure from Hardy-Weinberg Equilibrium (HWE) can be a sign
of genotyping error or population stratification. Top SNPs in controls that violate HWE
are removed from further machine learning analysis. Plink software [128] was used to
perform HWE with exact test since using chi-squared test is not suitable for multi-allelic
sites.
The research shows that it can predict GBM and LGG white individual cases and
1000 Genomes Project white individual controls with 90% mean balanced accuracy of
10-fold cross-validation (CV) when learning in best 10 germline variants selected by chisquared value with support vector machine (SVM) and random forest (RF). In crossstudy, learning with GBM+controls and predicting LGG achieved 89% balanced
accuracy, and 88% balanced accuracy the other way around.
The most contribution to the accuracy comes from SNP rs10792053. When this
SNP was removed, cross-validation mean balanced accuracy drops to 54% with top 10
SNPs, and 50% in cross-study. The research looked into the original alignments of SNP
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rs10792053 in cases and controls samples with the Integrative Genomics Viewer (IGV).
In both cases and controls, reads coverage and mapping quality at this locus were high.

5.2 Methods
5.2.1 Data
For case individuals, white normal samples (germline) whole-exome sequencing (WES)
data pre-aligned to Genome Reference Consortium Human Build 38 (GRCh38) in binary
alignment map (BAM) format were obtained from The Cancer Genome Atlas (TCGA)
through National Cancer Institute’s Genomic Data Commons (GDC) portal for two brain
cancer studies (males: 477, females: 331, mean age: 52.08). For control individuals,
Europeans samples WES pre-aligned to GRCh38 in CRAM format were downloaded
from 1000 Genomes Project phase 3 (males: 250, females: 297). This analysis considered
only white individuals, to reduce race differences effect on phenotype occurrence. It then
performed a variant calling workflow followed by a machine learning pipeline on these
samples. Table 5.1 summarizes cohort studies used in this analysis. Table 5.2 shows the
number of SNPs for 1000 Genomes Project, GBM, and LGG as well as common SNPs
after applying soft+hard filtering.
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Table 5.1 Samples Population
Population (sub-population)
1K Genomes Project (CEU)

Count
102

1K Genomes Project (FIN)

105

1K Genomes Project (GBR)

102

1K Genomes Project (IBS)

108

1K Genomes Project (TSI)

112

1K Genomes Europeans (all)

529

GBM white (not Hispanic)

274

GBM white (Hispanic)

5

GBM white (not reported)

58

GBM white (all)

337

LGG white (not Hispanic)

421

LGG white (Hispanic)

27

LGG white (not reported)

23

LGG white (all)

471

5.2.2 Joint Genotyping
For germline variant discovery, the Genome Analysis Toolkit (GATK) version 4 [39]
were used. GATK HaplotypeCaller variant calling walker produces an intermediate
Genomic Variant Call Format (GVCF) file for each sample. The intermediate GVCF files
of all samples were pooled together for genotyping by passing it to GATK
genotypeGVCFs to obtain a VCF file for samples cohort. Passing samples GVCFs with
the whole-exome regions is computationally intensive, to speed up the variants calling
workflow each chromosome is divided into roughly 10 equal intervals in a scatter and
gather fashion and were executed simultaneously on a cluster. Figure 5.2 illustrates the
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joint variant discovery workflow. After obtaining the final VCF file, quality control
measures were applied to reduce sequencing artifacts and false-positive genotypes.
5.2.3 SNPs Encoding
The output of the GATK GenotypeGVCFs tool is in a VCF format. In the header, it has
the reference base (REF), one of A, C, G, T, N bases, and alternate non-reference alleles
(ALT) base(s). It is possible but not common to have a multiallelic site (two or more
ALT bases). All permutations of genotypes were considered as input features to learn a
predictive model. An SNP encoding to a numerical value is an essential pre-processing
step to machine learning. Each SNP is encoded as follows:
4×X+Y

(5.1)

where A and B are the two alleles (copies) for a given sample at a particular locus of the
genome.

Figure 5.1 A toy example for encoding a multiallelic site.
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Table 5.2 SNPs Count after Applying Soft+Hard Filtering

1000 Genomes Project

Number of SNPs
184690

GBM

297106

LGG

485115

Common SNPs

118439

5.2.4 Missing Genotypes
In GATK, a genotype with low supporting reads is encoded as “./.” to denote no variant
call was made at that site for a given sample. Imputation is a method that is commonly
used in GWA studies to increase the number of genotypes in the as- sociation analysis.
Imputation algorithms predict ungenotyped loci in individuals that were genotyped on a
subset of loci of SNPs chip to boost SNPs array coverage utilizing haplotype information
across samples and HapMap data as an imputation reference panel [129-131]. This study
excluded column features that have a missing genotype in any sample from further
analysis. Thus, this eliminated the need for imputation.
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Figure 5.2 Germline SNPs calling pipeline with genome analysis toolkit performed on a
cluster to speed up computation.
5.2.5 Variants Calling Quality Control
GATK HaplotypeCaller by default excludes sites with mapping quality (MAPQ) ≤ 20.
This analysis used two layers of quality controls: SNPs soft filtering followed by hard
filtering to minimize false-positive SNPs. To confirm that the samples came from the
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same population, the research ran principal components analysis (PCA) on the whole
dataset before SNPs selection. In Figure 5.3, the projection of the first two components
shows that the samples are related. Two outlier samples were removed and PCA
projections of the first two components were replotted in Figure 5.4, and case and control
individuals do not form distinct clusters. Plink version (1.9) [128] were used to test for
departure from Hardy Weinberg equilibrium with an exact test in control samples. SNPs
that deviate from HWE were excluded. Only top SNPs in HWE are included in the
analysis, Table 5.3 shows the exact test p-values of top 10 SNPs in control individuals
from 1000 Genomes Project dataset.

Table 5.3 Hardy-Weinberg Equilibrium Exact Test P-Values
SNP
rs80356578

Observed Het
0.06049

Expected Het
0.05866

P-Value
1

rs150707706

0.03592

0.03527

1

rs143139551

0.03214

0.03162

1

rs145172249

0.04159

0.04072

1

rs148782546

0.02268

0.02243

1

rs10792053

0.2042

0.2069

0.6774

rs144518683

0.02268

0.2243

1

rs140561687

0.03025

0.02979

1

rs138772802

0.03403

0.03345

1

rs147042091

0.02836

0.02795

1

Note: Hardy-Weinberg equilibrium exact test P-values on top selected ten SNPs in control individuals from
the 1000 Genomes Project.
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Figure 5.3 Projection of principal component analysis with the first two components.

Figure 5.4 Projection of principal component analysis with the first two components
after excluding the two outlier data points.
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5.2.6 Soft Filtering
The soft filtering method assigns a probability for each variant call with GATK variant
quality recalibration score (VQSR) that uses machine learning by training on external
databases with known variant sites, and then it assigns a probability score to each variant
in the cohort. The truth sensitivity filter for VQSR were set to a 99.0% threshold. The
following VCF annotations with VQSR to build a recalibration model were used:
InbreedingCoeff, QD, MQ, MQRankSum, ReadPosRankSum, FS, SOR. variants that
failed soft filtering are removed from further analysis.
5.2.7 Hard Filtering
At the sample level, variant sites that have genotype quality (GQ) > 20 and depth (DP) >
5 for all samples are considered. DP is the number of reads to support the genotyping,
and GQ is a confidence score between 0 and 99, the higher the more confident the
program in its assigned genotype. BCFtools (version 1.3) [132] were used for hard
filtering and to extract VCF fields into table format.
5.2.8 Soft+Hard Filtering
Only SNPs that passed both soft filtering and hard filtering are considered for further
machine learning analysis.
5.2.9 Feature Scaling
Features with zero variance in training split were removed. The remaining features were
linearly transformed based on the training subset using Min-Max normalization to keep
the data between zero and one while preserving distance. Scikit-learn [116]
minMaxScaler were used and the implementation is as follows:
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Z
D24
=

D24 − min;D4 =
max;D4 = − min (D4 )

(5.2)

were D′24 is the current scaled value for the M KL individual in the JKL SNP, min (D4 ) and
max (D4 ) are the minimum and maximum values for JKL SNP, and max;D4 = − min;D4 = is
the range of the JKL SNP. We applied the exact same transformation to validation data
where we determined SNPs min and max from training data only.
5.2.10 Chi-Squared Features Selection
Top SNPs are selected based on the chi-squared statistic between each SNP and the label.
In the chi-squared test, a higher value is an indicator of dependence between the SNP and
the label. SNPs were ranked based on their chi-squared value using the scikit-learn chi2
function.
G
9

Χ = :
2

(!2 − 12 )9
12

(5.3)

where a is the number of classes, !2 is the sum of SNP alleles encoding for the M KL class.
?

,/ = ∑G2 !2 , and ,12 = G × /.
Table 5.4 shows the top chi-squared ranked 1000 Genomes Project+GBM+LGG common
SNPs.
5.2.11 Classifiers
Support vector machine (SVM) with linear kernel [81] and random forest (RF) [133]
classifiers were performed using scikit-learn package [116].
Support vector machine: SVM finds a hyperplane that maximizes the distance between
classes:
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‖e‖9
+ B max(0, 1 − H2 (e O D2 + ef ))
b,bc
2
min

(5.3)

where D2 is the genotype vector of the M KL individual, H2 is the label, e is the weight
vector, B is a regularization parameter, max (0, 1 − H2 (e O D2 + ef )) is the hinge loss and
the sign of (e O D2 + ef ) assigns the input D into class −1 or +1. We cross-validated the
hyperparameter B with 3-fold cross-validation from the set (0.1, 1).
Random forest: An ensemble method that builds decision trees by selecting random
samples with replacement to construct each tree and randomly generating a subset of
features to choose from for each candidate split, the one with the highest Gini impurity or
entropy, then it takes the majority vote of trees predictions to output a class prediction.
We used the default parameters for the quality measure of the split, and 3-fold crossvalidation from the set (100, 1000) for the number of trees to construct.
5.2.12 Performance Metrics
Since classes are imbalanced in the studies included in our analysis, it is inappropriate to
use accuracy as a measure of classifiers performance. We used balanced accuracy for
performance evaluation. Balanced accuracy is the average of true positive rate and true
negative rate.
65j, lmnM6Mo, 65j, a,0g6Mo,
k lmnM6Mo, + a,0g6Mo, p
Yghga7,i g77j5g7H =
2
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(5.3)

Table 5.4 Top SNPs for 1000 Genomes Project, GBM and LGG Datasets
Alt allele frequency
GBM+LGG
1K Genomes
0.0302
0.0068

SNP rs ID
rs80356578

Chi2 score
21.84

0.0180

0.0019

rs150707706

20.15

0.0161

0.0006

rs143139551

22.67

0.0208

0.0006

rs145172249

30.26

0.0113

0

rs148782546

18.33

0.1096

0.4963

rs10792053

50.63

0.0113

0

rs144518683

18.33

0.0151

0

rs140561687

24.44

0.0170

0

rs138772802

27.49

0.0142

0.0006

rs147042091

19.65

Table 5.5 Top SNPs for 1000 Genomes Project and GBM Datasets
Alt allele frequency
1K Genomes
GBM
0.0047
0.0237

SNP rs ID
rs140717526

Chi2 score
12.28

0.0038

0.0341

rs782010133

12.78

0.0076

0.0312

rs779492064

13.69

0

0.0134

rs202040378

14.13

0.0009

0.0148

rs146032550

12.51

0.0019

0.0386

rs759512484

34.27

0.0009

0.0163

rs76672487

14.05

0.0009

0.0148

rs148088117

12.51

0.1096

0.4926

rs10792053

42.67

0.0019

0.0341

rs768904765

24.25
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Table 5.6 Top SNPs for 1000 Genomes Project and LGG Datasets
Alt allele frequency
LGG
1K Genomes
0.0302
0.0074

SNP rs ID
rs80356578

Chi2 score
13.30

0.0076

0.0308

rs12721607

14.53

0.0009

0.0159

rs35723440

13.97

0.0208

0

rs145172249

19.59

0.0076

0.0297

rs2232449

13.60

0.0236

0.0032

rs61734485

14.88

0.0085

0.0329

rs2069548

14.84

0.1096

0.4989

rs10792053

45.18

0.0151

0

rs140561687

14.25

0.0170

0

rs138772802

16.03

5.3 Results
5.3.1 Cross-Validation
With chi-squared statistic best ten SNPs, linear SVM and RF achieved 90% mean
balanced accuracy of 10-fold cross-validation when predicting the 1000 Genomes Project
controls and GBM+LGG cases. The predictive ability deteriorates when all SNPs were
considered to 65% and 54% for SVM and RF, respectively. Figure 5.6 shows the results
for predicting three-classes of 1000 Genomes, GBM, and LGG with linear SVM, one-vsone. The mean balanced accuracy attained is 68% on top 10 SNPs, however, the accuracy
drops to 46% with all SNPs. The accuracy declines as more SNPs are added in both
binary and three-class classification of glioma subtypes individuals and control
individuals.
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Figure 5.5 10-fold cross-validation of learning and classifying binary labels.

Figure 5.6 10-fold cross-validation of learning and classifying 3-class labels.
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5.3.2 Cross-Study Validation
To test the generalization of the model, the research trained the data on GBM and
randomly selected 50% of 1000 Genomes samples and predicted the labels of the unseen
LGG dataset and the remaining 50% of 1000 Genomes samples. Top 10 ranked SNPs
obtained the highest balanced accuracy of 89%, again the advantage of ranking the SNPs
with chi-squared is shown, the accuracy drops when more SNPs are included to learn a
model. The worst accuracy of 63% was attained by considering all SNPs. The research
also tested the accuracy the other way around, where it learned in LGG and 50%
randomly selected samples from 1000 Genomes and predict the labels of GBM and the
remaining 50% samples of 1000 Genomes. It observed the same thing, where ranking the
SNPs with chi-squared boost the balanced accuracy from 60% with all SNPs to 88% with
only 10 SNPs. As expected, ranking SNPs by their dependence on labels improved the
balanced accuracy greatly on all cross-validation and cross-study validation experiments.
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Figure 5.7 Cross-study validation.

5.3.3 Cancer Significance of Top Ranked SNPs
A point mutation could be nonsynonymous (missense, or nonsense) or synonymous
(silent). Missense mutations, which is a change in a single nucleotide that substitutes
amino acid encoding and influences protein function [134, 135], are heavily investigated
in cancer research because it can alter protein function. Synonymous mutations are often
called silent mutations due to their inability to change the amino acid sequence, therefore,
these mutations usually are disregarded in cancer research [135]. However, synonymous
variants can affect protein folding, and thus it plays a role in cancer [136]. In this work,
we investigated both synonymous and nonsynonymous variants. SNPs rs76672487 (in
gene ABCC2) and rs2069548 (in gene TG) are cancer-related genes according to The
Human Atlas Protein. SNP rs76672487 ranked fifth on the selected SNPs by chi-squared
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from the GBM+1000 Genomes dataset, while SNP rs2069548 ranked fourth on
GBM+1000 Genomes top SNPs. From the 1000 Genomes+GBM+LGG datasets’ top ten
ranked SNPs six genes are reported by The Human Atlas Protein to be prognostic
markers for survival in glioma, liver, renal, cervical, urothelial, pancreatic, and
endometrial cancers based on gene expression FPKM values.

Table 5.7 All Datasets Genes Expression and Survival Time Association
Gene
OTOF

Survival prognostic marker in cancer
No

EAF2

Prognostic marker.

ALPK1

Prognostic marker.

LOC108783645, HFE

No

PTPRJ

Prognostic marker.

OR9G1

No

P4HA3

Prognostic marker.

ATF7IP

Prognostic marker.

PLBD1

Prognostic marker.

KCNC2

No

Note: top ranked SNPs genes expression and survival time association in the 1000 Genomes Project, LGG,
and GBM datasets based on The Human Atlas Protein database.

Tables 5.7 through 5.9 show top-ranked genes in the 1000 Genomes+GBM+LGG, 1000
Genomes+GBM, and 1000 Genomes+LGG datasets that are prognostic for survival time
in cancer. Five genes of the top-ranked in the 1000 Genomes+GBM+LGG dataset are
expressed in all cancers according to The Human Atlas Protein. KCNC2 gene is
expressed in breast and prostate cancers. P4HA3 gene is expressed in pancreatic, breast,
renal, glioma, and lung cancers. Genes OR9G1 and OTOF are not expressed in cancer.
Tables 5.10 through 5.12 show the genes that are expressed in cancer in top-ranked SNPs
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in the 1000 Genomes+GBM+LGG, 1000 Genomes+GBM, and 1000 Genomes+LGG
datasets.

Table 5.8 1000 Genomes and GBM Genes Expression and Survival Time Association
Gene
SARS

Survival prognostic marker in cancer
Prognostic marker

CA14

No

LHX9

No

DGKG

No

OSMR

Prognostic marker.

DMXL1

Prognostic marker.

ABCC2

Prognostic marker.

OR56B4

No

OR9G1

No

ZNF641

Prognostic marker.

Note: top ten ranked SNPs genes expression and survival time association based on The Human Protein
Atlas database.

Table 5.9 1000 Genomes and LGG Genes Expression and Survival Time Association
Gene
OTOF

Survival prognostic marker in cancer significance (P<0.001)
No

NR1I2

No

IGSF10

No

LOC108783645, HFE

No

MICAL1, ZBTB24

Prognostic marker.

CA1

No

TG

No

OR9G1

No

ATF7IP

Prognostic marker.

PLBD1

Prognostic marker.

Note: Top ten ranked SNPs in the 1000 Genomes Project and LGG and their genes expression and survival
time association as reported by The Human Protein Atlas database.
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Table 5.10 Top SNPs in All Datasets Genes and Functional Consequences
SNP rs ID
rs80356578

Gene
OTOF

Functional consequence
synonymous

Cancer mRNA expression
Not detected

rs150707706

EAF2

missense

Expressed in all

rs143139551

ALPK1

missense

Expressed in all

rs145172249

HFE

intron variant

Expressed in all

rs148782546

PTPRJ

synonymous

Expressed in all

rs10792053

OR9G1

synonymous

Not detected

rs144518683

P4HA3

synonymous

Mixed

rs140561687

ATF7IP

missense

Expressed in all

rs138772802

PLBD1

intron

Expressed in all

rs147042091

KCNC2

missense

Group enriched

Note: Top ten SNPs and their genes functional consequences in the 1000 Genomes project, GBM, and
LGG datasets as reported by The Human Protein Atlas database.

Table 5.11 Top SNPs of 1000 Genomes and GBM Genes and Functional Consequences
SNP rs ID
rs140717526

Gene
SARS

Functional consequence
missense

Cancer mRNA expression
Expressed in all

rs782010133

CA14

missense

Group enriched

rs779492064

LHX9

intron

Mixed

rs202040378

DGKG

intron

Tissue enhanced

rs146032550

OSMR

synonymous

Expressed in all

rs759512484

DMXL1

missense

Expressed in all

rs76672487

ABCC2

intron

Tissue enhanced

rs148088117

OR56B4

missense

Not detected

rs10792053

OR9G1

synonymous

Not detected

rs768904765

ZNF641

intron

Expressed in all

63

Table 5.12 Top SNPs of 1000 Genomes and LGG Genes and Functional Consequences
rs ID
rs80356578

Gene
OTOF

Functional consequence
synonymous

Cancer mRNA expression
Not detected

rs12721607

NR1I2

missense

Group enriched

rs35723440

IGSF10

synonymous

Mixed

rs145172249

HFE

intron

Expressed in all

rs2232449

ZBTB24

synonymous

Expressed in all

rs61734485

CA1

missense

Group enriched

rs2069548

TG

missense

Tissue enriched

rs10792053

OR9G1

synonymous

Not detected

rs140561687

ATF7IP

missense

Expressed in all

rs138772802

PLBD1

intron

Expressed in all

5.3.4 SNP rs10792053 Mapping Quality
To confirm that there is no issue with reads mapping quality or coverage, eight
individuals from both cases and controls alignments were inspected with the Integrative
Genomics Viewer (IGV) in the original reads mapping at locus 11:56701017 and its
adjacent loci. Figure 5.8 shows alignments with IGV of four samples from cases vs four
from controls against the GRCh38 reference genome. The red arrow in Figure 5.8 points
SNP rs10792053 position. The tangerine color in the tracks at the position refers to allele
C and the green refers to reference allele A.
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Figure 5.8 Alignments of four cases vs four controls at SNP rs10792053 the upper four
tracks for cases (LGG, GBM) viewed with IGV.
In IGV, if both allele copies in the sample is homozygous reference, then it is
shown in gray. Three of the four cases viewed are heterozygous and the remaining one is
homozygous alternate allele. All controls in Figure 5.8 are homozygous reference. In
IGV the mapping quality threshold were set to 1 since GATK HaplotypeCaller discards
reads with a mapping quality of 0. The original alignments of both cases and controls
have high coverage at this location. Although GATK HaplotypeCaller reassembles
alignments at active regions and discards original alignments, the final VCF is consistent
with what is observed in original alignments. For SNP rs10792053, the average depth
across all cases is 407.15 and across all controls is 63.58. These average depths are after
running the GATK germline variant discovery workflow. The research tested for Hardy
Weinberg equilibrium exact test in controls individual and the p-value is 0.677, which
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confirms that this SNP is in HWE, however, it is out of HWE in cases.
5.3.5 Alternate Allele Frequency of Top SNPs
Table 5.13 shows the alternate allele frequency of dbSNP 1000 Genomes Project
Europeans samples, GBM, LGG and 1000 Genomes Project samples that are considered
in this study, which is slightly larger than 1000 Genomes sample size in dbSNPs since
this study downloaded samples from 1000 Genomes Project phase 3.

Table 5.13 Cases and Controls Top Ranked SNPs Alternate Allele Frequencies
rs ID
rs80356578

dbSNP (EUR)
A=0.029

Controls
0.0302

Cases

rs150707706

C=0.019

0.0179

0.0018

rs143139551

A=0.017

0.0160

0.0006

rs145172249

C=0.019

0.0207

0.0006

rs148782546

T=0.012

0.0113

0

rs10792053

G=0.116

0.1096

0.4962

rs144518683

C=0.012

0.0113

0

rs140561687

T=0.016

0.0151

0

rs138772802

C=0.017

0.0170

0

rs147042091

C=0.013

0.0141

0.0006

0.0068

Note: 1000 Genomes Project (Controls) and GBM+LGG (Cases). The third and fourth columns contain the
alternate allele frequencies in this research (white individuals). The second column shows the reported
allele frequencies by dbSNP (European samples) database.

For example, SNP rs80356578 sample size in dbSNP is 503 and the sample size
for our 1K Genomes is 526. Our alternate allele frequency is close to what is reported by
dbSNP for 1000 Genomes Project Europeans samples.
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5.4 Conclusion
This chapter shows that it can predict glioma cases with few germline SNPs selected
based on the chi-squared statistics with 90% mean balanced accuracy in cross-validated
TCGA-GBM and TCGA-LGG white individual cases and 1000 Genomes Project
Europeans controls whole-exome sequences with linear SVM and random forest
classifiers. The chapter also shows that in cross-study linear SVM achieves 89%
predictive accuracy when learning with GBM and 1000 Genomes Project controls and
predicting LGG and 88% contrariwise on the top-ranked germline SNPs. However, most
of the accuracy comes from SNP rs10792053, a replication study is needed to verify its
discriminative power in glioma.
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CHAPTER 6
CHALLENGES IN PREDICTING GLIOMA SURVIVAL TIME IN MULTIMODAL DEEP NETWORKS

6.1 Introduction
Predicting glioma survival time helps patients and their clinicians evaluate available
treatment plans and make informed choices. Glioblastoma Multiforme (GBM) is the most
common and lethal glioma type in adults [137]. In GBM, less than 5% of patients reach
five years survival threshold after diagnosis with a median survival time of 15 months
[138]. Most advanced cancer patients prefer to know their estimated prognostic
information [11]. However, clinicians’ survival time estimates are inaccurate and often
optimistic [11, 12].
Many studies have devised 3D convolutional neural networks (CNNs) to improve
the accuracy of structural MRI scans to classify glioma patients into survival categories
[3, 13-15]. This work looks into a heterogeneous combination of somatic and germline
genetic single variations, messenger RNA expressions, and post-contrast T1 MRI
modality data that show the malignancy. Whole exome sequencing data (WES) were
obtained from The Cancer Genome Atlas (TCGA) portal (https://www.cancer.gov/tcga),
messenger RNA, and post-contrast axial T1 MRI sequences from The Cancer Imaging
Archive (TCIA [139]) for all European ancestry individuals with GBM. In this analysis,
only samples for which all three data types are available were included, which gives a
total of 126 samples. Each sample is assigned a label of zero if the survival time is
below14 months and a label of one otherwise (to obtain a balanced set), thus converting
the survival time prediction problem into a classification one.
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This work designed a multi-path neural network that takes as input all three data
sources and evaluates its accuracy in a 10-fold cross-validation experiment. Genome
Analysis Toolkit (GATK4) pipeline was performed to obtain single mutations with
exhaustive site-level and sample-level quality controls to eliminate sequencers artifacts
and false-positive SNPs. Both and multiallelic loci were included, and the two allele
copies of each SNP were converted into a numerical format using an in-house python
script. Then, SNPs were ranked on each training split to select the best 100 SNPs to use
as predictive markers. The mRNA expression information for the TCGA-GBM was
obtained from the Broad Institute TCGA Genome Data Analysis Center Firehose after
Robust Multi-array Analysis (RMA) normalization.
MRI sequences in Digital Imaging and Communications in Medicine (DICOM)
format were downloaded from TCIA. From the 3D axial T1 MRI sequences. Both 3D
volumes and 2D slices were explored. For 3D scans, the DICOM images were converted
to the Neuroimaging Informatics Technology Initiative (NIfTI) format. The non-brain
tissue was extracted with FSL BET, and the images were registered to T1 MRI MNI152
reference with FSL FLIRT. A model was trained with 3D U- Net [140] separately as well
as simultaneously with SNPs and mRNA data.
For 2D slices, one slice that shows the tumor for each sample was manually
selected. Then these 2-D image slices were used to train a 2D CNN with ResNet18 [141]
encoder and measured the accuracy of predicting test samples in 10-fold cross-validation.
This study compared the accuracy of predicting survival time with SNPs, mRNA
expressions, and MRI scans separately as well as when combining the three data sources.
For SNPs and mRNA expressions, separate multi-layer neural nets were used, and for
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images, 2D and 3D convolutional neural networks were explored.
A slight improvement within combined model with 2D images is observed over
the individual data sources but considerable variation in test accuracy across different
train test folds. This work conjecture that this may be due to the small training set of 126
individuals. By synthetically augmenting the data with a generative model, this research
may improve sample representation and consequently model accuracy.

6.2 Methods
6.2.1 Data
Data

is

composed

of

TCGA-GBM

European

ancestry

individuals

(https://www.cancer.gov/tcga) that have all of the following data: 1) Survival time (days
from diagnosis to death), also, right censoring to increase the dataset size was performed,
where samples for which days to the last follow-up are above the 14 months threshold
were included, 2) WES data, 3) mRNA expressions information, and 4) post-contrast T1
axial MRI sequence. Samples that do not meet the inclusion criteria were excluded. The
total number of samples included in the analysis is 126. Table 6.1 shows the clinical
characteristic of these samples.
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Table 6.1 Samples Clinical Characteristics
Clinical Characteristics
Ancestry (European)

TCGA-GBM
126

Ethnicity (not reported/not Hispanic)

25/101

Gender (male/female)

76/51

Average age

60.38 ± 13.37

Vital status (dead/alive)

123/3

Average survival (days)

483.44 ± 431.95

# of samples in each class (short-term/long-term)

63/63

SNPs:

TCGA-GBM 126 European ancestry individuals pre-aligned WES for each

sample

that

met

the

inclusion

criteria

were

obtained

from

the

TCGA

(https://www.cancer.gov/tcga) through the NCI Genomic Data Commons (GDC) data
portal (https://gdc.cancer.gov/). GATK (version 4) HaplotypeCaller [38, 39, 76] was
performed on each sample. All samples were then pooled together for joint genotyping
utilizing a computing cluster in a scatter and gather approach on each chromosome to
expedite variant discovery process. To filter out low-quality SNPs, the GATK variant
quality recalibration score (VQSR) was performed, which uses a machine learning
trained on external datasets to assign a quality score to each site-level variant. The truth
sensitivity of 99% as a threshold is used for VQSR. Those SNPs that passed VQSR are
further interrogated on sample- level genotype quality (GQ) and depth (DP). SNPs that
passed VQSR at the site-level and GQ > 20 and DP ≥ 5 at the sample-level are included
for further analysis. This work performed the widely used multi-allelic encoding of SNPs
shown in Figure 6.1.
The chi-squared statistic [142] between each SNP and the binary class label was
calculated, and SNPs were ranked based on the test statistics. The higher the statistic, the
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more important the SNP in its predictive ability. We included top-ranked 100 SNPs for
further analysis.
mRNA expressions: Gene expression information was downloaded for the samples that
were normalized with Robust Multi-array Analysis (RMA) from the Broad Institute
TCGA Genome Data Analysis Center Firehose [143].
3D MRI scans: Axial T1 MRI sequences in DICOM format were obtained from The
Cancer Imaging Archive (TCIA). DICOM images were converted to NIfTI format with
dcmtonii software, and non-brain tissue was removed with FSL BET [144] with option B (an option that leads to overall better performance in skull-stripping [145]). Then
images were aligned to T1 axial MNI152 reference with FSL FLIRT.
2D MRI slices: For each subject, an image slice was manually selected that best shows
the tumor and its surrounding tumor enhancing-area. Table 6.2 shows the vector and
matrix dimensions for the three data sources that were used in this analysis.

Table 6.2 SNP, mRNA, and T1 MRI Data
Dataset
SNPs (passed filtering)

Vector (matrix) dimension
79980

mRNA expressions

12042

3D post-contrast T1 MRI scans

(182, 218, 182)

2D post-contrast T1 MRI slices

(256,256)
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Figure 6.1 Multiallelic SNP encoding into a numerical values example.
6.2.2 Network Architecture and Training
Three separate neural nets were constructed using PyTorch [146] to evaluate the
predictive power of each data source alone. the output of these nets was concatenated to
evaluate combining SNPs, mRNA expressions, and images predictive ability.
For SNPs, a neural net with two hidden layers was constructed. Relu activation
function, 0.01 learning rate, batch size of five, and 30 epochs with Stochastic Gradient
Descent (SGD) [147] and Nesterov Momentum update. For mRNA expressions, the
parameters were set to exactly what was used for SNPs but with three hidden layers
(1000, 100, 10). For 2D T1 MRI sequence slices, ResNet18 convolutional neural network
[141] was used which has 18 hidden layers and has 18 output nodes. Because the
ResNet18 input size shape is (244, 244), all slice images were resized to (256, 256)
dimensions and randomly center cropped (224, 224), the cropped images were used as an
input for the ResNet18 convolutional neural network. The following parameters with
ResNet18 were used: learning rate of 0.01, batch size of 6, 15 epochs. For 3D volumes,
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the 3D U-Net [140] where employed, and the original images were padded with zero to
fit the network input dimensions (192, 224, 192). The same hyperparameters that were
used to train the 2D slices in ResNet18 were used for the 3D U-net.

Figure 6.2 Proposed multi-modal deep neural network. One can see three paths each for
SNP, gene expression, and images. The study trains the network as one model instead of
training the three paths separately.
To combine each of SNPs and mRNA dataset with MRI slices, a one more dense layer
was added to the end of ResNet18. After Relu activation, the output was concatenated to
the network’s output. Then, it was fed into a dense layer with 50 input nodes and two
output nodes. For combining the three data sources, all the three outputs of each network
were concatenated. Figure 6.2 shows the network architecture for combined data sources.
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6.3 Results
Here the 10-fold cross-validation results on all three data sources combined as well as
individual data sources with both 2D and 3D images is reported. The accuracy is
evaluated as the sum of correct predictions over the total number of the test set. Survival
threshold at 14 months was intentionally selected so that the data is balanced: the number
of samples in both classes is equal.
6.3.1 Combined Data with 3D Volumes
Figure 6.3 shows the mean accuracy of our model across 10-folds and 15 epochs for each
of the three data sources separately and the combined data model. The model with
combined data sources can achieve a 100% accuracy on the individual and combined data
models. In the test, however, the accuracies are lower. The combined data model does not
perform better than the individual ones. In fact, here the gene expression data source
gives the best test accuracy of 62.4% at epoch 13.

Figure 6.3 Mean 10-fold accuracy of our network across 15 epochs for training and test
sets with 3D volumes as the image data.
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Figure 6.4 shows the test accuracy of each of the ten folds of the combined model.
In some folds, the test accuracy goes to 75%, whereas in others as low as 25%. This
suggests that some folds have a diverse enough training set that captures the distribution
of test data points, whereas, in other folds, the training and test image datasets are very
different.

Figure 6.4 Test accuracy of each of the 10-folds of our network across 15 epochs on all
three data sources combined with 3D volumes as the images.
6.3.2 Combined Data with 2D Slices
Figure 6.5 shows the mean 10-fold accuracy on training and test sets across 15 epochs of
the model with 2D slices as images. Here one can see an overall better test accuracy with
the combined model but by a small margin. At epoch 11, the combined data gives 63%
accuracy, whereas the gene expression alone gives 62.4% at epoch 13. This difference,
however, is not statistically significant.
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Figure 6.5 Mean 10-fold accuracy of our network across 15 epochs for training and test
sets with handpicked 2D slices (that manifest the tumor) as the image data).
The test accuracy of each of the ten folds on the combined data, one can see a
considerable variation, as shown in Figure 6.4. Again, this shows that in some folds, the
train and test distributions are likely to be the same, while in others, the distribution is
very different, thus making it hard to classify.

Figure 6.6 Test accuracy of each of the 10-folds of our network across 15 epochs on all
three data sources combined with 2D slices as the images.

77

6.4 Discussion
Combining data into three sources yields a slight improvement that is not statistically
significant. Clearly, by simply combining more data, one cannot expect to predict
survival time accurately, but this study also possibly needs to enlarge the training set size.
The variation in test accuracy across the folds suggests model instability, which is
attributed to insufficient data. One possible avenue to solve this is to generate artificial
samples for all three sources with a generative model like a generative adversarial
network [148].
Another thing in the results is the 100% accuracy in training on the combined data
in both 2D and 3D. Could the model be overfitting? A dropout [149], which is a popular
and powerful method to reduce overfitting, was added. It reduces the training accuracy all
the way down to in the 50-60% range and does not improve test accuracy. This suggests
we may need a richer model with dropout since even fitting training samples becomes
very hard with this method.
Finally, one can see that the 2D combined model performs better than the 3D. A
3D model, in general, requires much more data than a 2D, which is one likely reason for
the 3D model’s poorer performance. The 3D U-Net was fine-tuned, but it did not improve
accuracy. Again, the research conjecture that additional data points via generative
modeling may increase accuracy.

6.5 Conclusion
Integrating genomic and neuroimages in a multi-path neural network slightly improve
glioma survival time prediction at the 14-month threshold. One can see instability in test
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accuracy in the model, and this study conjecture that a larger sample size produced via a
generative model may improve stability and overall accuracy.
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CHAPTER 7
MULTI-PATH CONVOLUTIONAL NEURAL NETWORK FOR
GLIOBLASTOMA SURVIVAL GROUP PREDICTION WITH POINT
MUTATIONS AND DEMOGRAPHIC FEATURES
7.1 Introduction
Glioblastoma multiforme (GBM) is the most common and aggressive type of brain
cancer, with a median survival rate of 15 months [10]. Untreated patients with GBM have
a median survival time of 3 months [150]. It is well-established that age is a strong
independent predictor of survival time in gliomas [151-153]. Several studies have found
that gender is significantly correlated [154-156]. A study that analyzed 6586 GBM
patients shows that age and gender, among other seven features, are independent survival
prognostic factors [157]. Other studies investigated the role of Single Nucleotide
Polymorphisms (SNPs) on GBM overall survival outcomes [158, 159]. One study found
that GBM patients who carry both TERT mutations and homozygous C-allele mutation
for SNP rs2853669 have shorter survival time versus patients with wild-type allele [160].
There is accumulating evidence in the literature that GBM patients with IDH1 somatic
mutation have significantly higher overall survival time compared to patients who carry a
wild-type allele [161-163].
This work hypothesizes that combining tumor sample’s SNP, age, and gender
data increases the predictive power of GBM survival outcome. The research proposes a
multi-path neural network to predict short (< one-year) and long (≥ one-year) survival
groups. The predictive ability of combined SNPs, demographic features (age, age groups,
and gender) versus each data source alone was assessed, and the proposed method was
compared to support vector machine (SVM) with linear kernel, and random forest
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classifiers.
This study downloaded The Cancer Genome Atlas Glioblastoma Multiforme
(TCGA-GBM) of 272 white individuals demographics (age, gender), survival (days from
diagnosis to death), and tumor samples’ pre-aligned whole-exome sequencing data from
National Cancer Institute’s Genomic Data Commons (GDC) portal. To obtain SNP data
from sequence alignment files, a variant calling workflow was performed with Genome
Analysis Toolkit (GATK, version 3.8) [39, 76] followed by two-layers quality controls:
1) variant quality score recalibration (VQSR), and 2) hard filtering (depth < 5, genotype
quality < 20). SNPs that have any missing value were excluded from further analysis.
The pipeline randomly held out 10% of the whole data set, 5% from each class to
create a balanced subset, and kept it as a test set. The other 90% of data was used for
training and hyperparameters tuning by employing 10-fold cross-validation. The pipeline
then fit a model with the 90% of data that is kept for training with best-performing
hyperparameters and predict the test data set. The accuracy of SNPs alone, age and
gender alone, and combined SNPs, age, and gender were reported. The research then
compares the performance of the proposed method to SVM and random forest.
On the test dataset, the best classification performance is reached by feeding SNP
and demographic features into the proposed multi-path convolutional neural network.
There we achieved an accuracy of 67%, where linear SVM and random forest attained an
accuracy of 60% and 46%. When considering demographic features alone, the linear
SVM has 60% accuracy, our method has an accuracy of 60%, and random forest reaches
53% prediction accuracy.
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7.2 Methods
7.2.1 Patients Cohort
TCGA-GBM data were obtained for all white individuals that have tumor sample’s
binary alignment map (BAM) files, survival information (days from cancer index to
death), and demographic features (age and gender) from NIH’s GDC portal. A total of
272 patients met the inclusion criteria. The pipeline converted age, and gender into
numerical values, and also created an age group binary feature with 70 years threshold
since GBM patients with age ≥70 have significantly lower survival time [164]. Table 7.1
shows GBM patients’ characteristics.

Table 7.1 Cohort Characteristics

Short-/long-term survival
Average age
Age ≥70
Male/female

n=272
128/144
61.14 (±12.83)
71
177/95

7.2.2. SNPs Calling and Quality Control
Variants calling were performed with tumor samples only, and GATK HaplotypeCaller
(version 3.8) [39, 76] was used. GATK scans samples’ genomes to identify regions with
variability that exceed a defined threshold. From these regions, it builds an assembly
directed graph with a reference genome as a template. It uses the most likely graph paths,
the ones that have higher read data, to list candidate haplotypes. The candidate haplotype
sequences are aligned against the reference genome with the Smith-Waterman algorithm
to produce a CIGAR string. GATK determines the likelihood of haplotype by aligning
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every read against each haplotype with the PairHMM algorithm, which gives a likelihood
for each haplotype given read data. From read data likelihoods, the program assigns allele
likelihoods (possible genotypes). Finally, GATK uses Bayes’ Theorem to assign
genotypes for each sample from the list of possible genotypes.
All subjects’ samples were pooled together for variant discovery. To speed up the
variants calling stage, each chromosome was cut into roughly ten equal chunks and
executed at the same time on a cluster in a scatter-gather approach. In the final variant
call set, the GATK variant quality score recalibration (VQSR) algorithm was performed,
which uses machine learning to filter out low-quality variants. After applying VQSR
filtering (soft filtering). The truth sensitivity filter for VQSR was set to a “99.0%”
threshold. We used the following annotations with VQSR to build a recalibration model:
InbreedingCoeff, QD, MQ, MQRankSum, ReadPosRankSum, FS, SOR. This study also
filtered out variants that have a depth (number of supporting reads) ≤ 5 or genotyping
quality ≤ 20. Also, non-SNPs variants and sites that have any missing value were
removed. The final output contains a matrix of SNPs and samples. Each SNP column is
in the form A/B where A and B are the two alleles copies. Table 7.2 shows the number of
SNPs after applying each filtering method.

Table 7.2 TCGA-GBM SNPs Count after Applying Three Filtering Methods
Filtering method
Soft filtering (VQSR)

Number of SNPs
304302

Hard filtering

155673

Soft+hard filtering

107777
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7.2.3 SNPs Encoding
To encode an SNP into a numerical format to perform machine learning tasks, the
formula: 4 × A + B were used, where A and B are the two alleles copies for a given
individual sample. This study multiplies A by 4 to consider all permutations in a
multiallelic site (the maximum alternate alleles for an SNP is 3). For example, if an
individual is homozygous at the third alternate allele for a particular SNP, then this
specific SNP encoding is 15. SNPs were sorted in increasing order according to their
genomic position.
7.2.4 Training and Test Sets
Separate training and test data sets were created to ensure the validity of the results. In
the original TCGA-GBM dataset of 272 samples, the pipeline shuffled the data and
randomly selected 5% from each class, to get a balanced subset, and kept this 10%
balanced dataset for model testing. The remaining 90% was used for hyperparameters
tuning, by employing 10-fold cross-validation, and to fit a model to predict the unseen
test dataset with the best performing hyperparameters. Table 7.3 displays patients’
characteristics in training and test data sets.

Table 7.3 Training and Test Sets Characteristics

Survival < 1 year

Training set n=244
114

Test set n=28
14

Survival ≥ 1 year

130

14

Average age

61.1 (±12.5)

61.4 (±14.6)

Age ≥70

62

9

Male/female

157/87

20/8
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7.2.5 Hyperparameter Selection
Classifiers hyperparameters, such as the SVM C regularization value, need to be set
before model training begins, and thus are not optimized during the learning stage. To
choose the best learning rate and the number of epochs hyperparameters for the proposed
neural network, all possible pairs in the Cartesian product of the two sets were evaluated:
learning rate = (0.001, 0.01, 1) and the number of epochs = (1,2,3, ..., 20) using 10-fold
cross-validation in the 90% of the original dataset (number of samples= 244) that are kept
for training. This research also employed the same method, with the same data in each
fold, to select the best regularization C hyperparameter from the set C= (0.01, 0.1, 1) for
linear SVM, as well as the number of trees to grow for random forest from the set (10,
100, 1000). The pipeline then fits a model on the whole training dataset with the best
performing hyperparameters and uses the model built to predict the unseen 10% of the
original data that was reserved as a test dataset.
7.2.6 Classifiers
Convolutional Neural Network (CNN):

CNNs typically are stacked layers of

convolution operations with pooling (downsampling of original data for training
efficiency) and batch normalization layers in between convolutional layers. The
convolution runs on sliding windows of a specified size and fixed step size, to control the
moving dot product over training data. A non-linear and differentiable activation
function, such as a rectified linear unit (Relu), is then applied to the flattened output.
Multi-path Model: The research proposes a new neural network system, where it feeds
the network two inputs: 1) SNPs data, 2) demographic data (age, age groups, and gender).
Since SNP data were sorted in an increasing order based on its genomic position, the
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SNPs were passed through a series of 1D convolutions, with different kernel sizes and a
step size of one, Relu activation function, 1D average pooling, batch normalization
layers. Simultaneously, the pipeline fed the three demographic features into two hiddenlayers and merge the two paths and train the weights together through three fully
connected layers. Then the network passes the weights into a sigmoid function that
outputs a value between zero and one. If the output is ≥ 0.5, the network assigns it to
class one, and class zero otherwise. The network trained the model with stochastic
gradient descent with a momentum that was set to 0.9. The pipeline used 10-fold crossvalidation to select the number of epochs and learning rate (lr) value. The batch size was
set to 128. Figure 7.1 shows the multi-path model’s architecture, all input and output
shapes, and convolutions kernel and average pooling sizes. The network is implemented
using Keras library [165].
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Figure 7.1 The proposed multi-path model architecture with SNP and demographic
features.

87

Single-path Model: The research compares fitting a combined SNP and demographic
features with our multi-path model to fitting a single-path 1D convolutional neural net
with SNPs only and with three demographic features alone neural network.
Support Vector Machine (SVM): SVM with a linear kernel was used. Briefly, SVM
finds a hyperplane that maximizes the distance between the two classes’ data points that
are closest to the margin (support vectors). In its soft-margin version, SVM allows
misclassification of noisy data points and introduces a trade-off hyperparameter C that
needs to be tuned. As C approaches infinity, the classifier gets closer to the hard-margin
solution. The pipeline uses 10-fold cross-validation to select the best performing C in the
training dataset. The research compared combining SNP and demographic features to
fitting an SVM model with each data source individually. For SVM and random forest
experiments, the scikit-learn library [116] was used.
Random Forest: Random forest is an ensemble method that constructs many decision
trees by choosing random samples with replacement to build each tree and randomly
generates a subset of features to select from for each candidate split, usually the one with
the highest Gini impurity or entropy, then it takes the majority vote of all trees
predictions to output a class prediction. The default parameters for the quality measure of
the split were used. The pipeline employed 10-fold cross-validation to select the optimal
hyperparameter for the number of trees to construct. The pipeline fits a model with
combined SNP and demographic features, SNP alone, and age+age group+gender
individually.
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7.2.8 Evaluation Metrics
Accuracy, which is the number of correctly classified samples over the number of all
predicted samples, was used to measure classifiers’ prediction power in the test data set.
However, in training and validation data sets, we used the balanced accuracy, which is
the average of true positive rate and true negative rate, since it has imbalanced class
distribution.

7.3 Results
7.3.1 Cross-Validation
In the training set, the pipeline performed 10-fold cross-validation to select the best
number of epochs and learning rates for single- and multi-path neural network system.
Figure 7.2 shows the mean balanced accuracy attained with different learning rates and
the number of epochs across the ten folds. The best mean balanced accuracy of 63%
(±0.08) across ten folds is realized when we fed both SNP and demographic features into
our multi-path model with 0.01 as the learning rate. The mean balanced accuracy slightly
drops after it reaches its peak at the 13th epoch. With SNP data alone, the best learning
rate was 0.001 with nine epochs, where the single-path convolutional neural network
attained 54% (±0.12) mean balanced accuracy. With the demographic features alone, the
single-path neural network reached its highest mean balanced accuracy of 59% (±0.12) at
epoch 14 with a learning rate of 0.1.
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Figure 7.2 Cross-validation average balanced accuracy across 10-folds as a function of
the number of epoch and learning rate for multiple data inputs: demographic
characteristics (age+age groups+gender) only, SNPs only, or SNPs and demographic
characteristics combined. Each line color, which is shown in the series color legends,
represents input data (learning rate in parentheses).
SVM C regularization hyperparameter and the number of trees to grow for
random forest classifiers were tuned. Figure 7.3 shows that the SVM achieved its best
results when C= (1, 0.1), where both values are equally the best in combined SNP and
demographic features, SNP alone, and demographic features alone. When learning with
demographic features alone, SVM attained 61% (±0.08) mean balanced accuracy. SVM
achieved 56% (±0.11) mean balanced accuracy with SNPs data alone, and the mean
balanced accuracy drops to 50% (±0.10) when combining SNP and demographic
features.
For random forest, setting the number of trees to 10 yielded a better performance
for SNPs alone with 50% (±0.12) mean balanced accuracy and demographic features
alone 52% (±0.08) mean balanced accuracy. In combined SNPs and demographics, with
the optimal number of trees of 100 that was selected with cross-validation in the training
set, achieved 49% (±0.11) mean balanced accuracy. Figure 7.3 shows the average 10-fold
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cross-validation with different hyperparameters for SVM and random forest.
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Figure 7.3 Cross-validation mean balanced accuracy across 10-folds with linear SVM
(with different C regularization values) and random forest (with different number of trees
values) and multiple data inputs: demographic characteristics (age+age groups+gender)
only, SNPs only, or SNPs and demographic characteristics combined. Each bar color
represents a data source.
7.3.2 Test Set Prediction Performance
After cross-validating, the optimal hyperparameters for each classifier with each data
source. The pipeline fits a model on the full training and validation sets and predicts an
independent and balanced test set. Table 7.4 shows the accuracies attained by the
proposed model, SVM, and random forest accuracies with and without combining SNP
and demographic features. The proposed multi-path model, with combined SNP and
demographic features (age, age group, and gender), achieved the highest classification
accuracy of 67%, when learning with the optimal hyperparameters that were selected
with the 10-fold cross-validation: learning rate of 0.01, and 13 epochs.
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Table 7.3 Prediction Accuracy on Test Set with the Optimal Hyperparameters

Our method
SVM
Random forest

SNP and demographic
0.67
lr =0.01
epoch =13
0.60
C =1
0.46
# of trees =10

SNP
0.60
lr =0.001
epoch =9
0.57)
C =1
0.50
# of trees =10

Demographic
0.60
lr =0.1
epoch =14
0.60
C =1
0.53
# of trees =100

Combined SNP and Demographic Features: When combining SNP and demographic
features, the proposed multi-path model achieved an accuracy of 67%, which
outperformed both SVM (60%) and random forest (47%) accuracies. Furthermore,
passing SNP, age, age groups, and gender yielded a nicer training curve that is stable
across training epochs. Figure 7.4 compares the training balanced accuracy of the
combined SNP and demographic features with SNP data alone and demographics
individually.

Figure 7.4 Training accuracy on training set (n=244) for combined SNP and
demographic features, and each data source individually.
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SNP and Demographic Features: In the test set, fitting a model with SNPs individually
or age+age groups+gender alone had lower accuracy than combining SNPs and
demographic features. With SNP data only, the proposed single-path CNN had an
accuracy of 60% with a learning rate of 0.001 and 9 epochs. SVM achieved an accuracy
of 57% with C=1, and random forest accuracy is 50% with 100 trees. Figure 7.5 displays
the proposed model prediction accuracy with different data sources on the test set. With
demographic features alone, SVM and the proposed single-path neural network
performed equally with 60% accuracy. Random forest attained 50% accuracy. Table 7.4
compares the accuracy achieved by the proposed CNN, SVM, and random forest with
combined SNP and demographic features and with each data source individually.

Figure 7.5 Test set prediction accuracy for combined SNP and demographic features,
and each data source alone.
7.4 Conclusion
This chapter proposes a new multi-path convolutional neural network for combined SNP
and age, age group, and gender that improved upon SVM and random forest in terms of
model accuracy in cross-validation and an independent test set. The research shows that
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using combined SNP and demographic features in a multi-path network attains a better
classification performance than each data source individually and stabilized the learning
process.
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